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Abstract 
According to the survey (Gaudett et a!. 1998, 1996), cancer is the number one disease 
that causes death in Canada and U.S. Many approaches have been used to treat cancer. 
Chemotherapy has played and will continue to play an important role in caner treatment. 
Although many anticancer drugs are available, there are serious problems associated with 
cancer chemotherapy including toxicity and development of drug resistance. Retinoids 
such as all-trans retinoic acid, omega-3 polyunsaturated fatty acids such as cis-
4,7,10,13,16,19-docosahexaenoic acid (DHA) and fluoropyrimidines such as 5-fluoro-2'-
deoxyuridine (FUdR) have potent distinct anticancer mechanisms. Since many cancer 
cells are known to overexpress low density lipoprotein (WL) receptors, LDL has been 
proposed as a cancer specific carrier. In this study, LDL was investigated as a drug 
carrier to enhance the drug delivery to cancer cells (Hela, MCF7, MB231 and HepG2 cell 
lines). Four derivatives of FUdR (3' -0-retinoyl-FUdR, 3' -0-docosahexaenoyl-FUdR, 5'-
0-retinoyl-FUdR and 3', 5' -di-0-retinoyl-FUdR) were synthesized as prodrugs of FUdR. 
The prodrugs were incorporated into LDL. The results showed that the cytotoxicity of the 
respective prodrugs was increased compared with parent drug FUdR. The prodrug/LDL 
complex was more effective than the prodrug without LDL as a carrier in Hela cells. 
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Chapter 1 Introduction 
1.1 Cancer and Chemotherapy 
Cancers are diseases in which unremitting clonal expansion of somatic cells kill 
normal cells by invading, subverting and eroding (Evan et al. 2001, 1998). According to 
Gaudette's survey (Gaudette et al. 1996, 1998), cancer is one of the leading causes of 
death in Canada and the U.S. It is estimated that one in every three Americans will 
develop cancer in their lifetime (Leszczniecka et al. 2001). Data (Parkin et al. 2001) 
indicate that lung cancer and breast cancer are the most common cancers in the world. 
It is recognized that cancer progression is a complex, multi-step process. 
Numerous factors may induce cancer including environmental factors and genetic factors 
(Haldane et al. 1985). Environmental factors include chemicals, biological and physical 
agents (Tomatis et al. 1997, Strickland et al. 1995, Weichselbaum et al. 1989, Mann et 
al. 1987). Evidence indicates that smoking, alcohol, certain medications, electromagnetic 
radiation and infection play crucial roles in neoplasm (Montesano et al. 2001, Doll, 
1999). For example, tobacco is known to be associated with various cancers, especially 
lung cancer (Parkin et al. 1994, Doll et al. 1994, Liu et al. 1998, Niu et al. 1998). While 
many cancers are believed to be closely linked to environmental factors, some cancers are 
due to inherited mutations in certain genes and genetic susceptibility causes a large 
proportion of cancers (Peto et al. 2001). Many factors are known to enhance genetic 
·susceptibility and the most important ones are immune system, aging and living 
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environment. The host immune system, especially a weakened immune system, is often 
not sensitive enough to respond to the self-cellular malignancy process (Wooldridge et al, 
2003). Inside mammalian cells, there are two components: a nucleus and its surrounding 
cytoplasm. Division of nucleus into two daughter nuclei occurs at mitosis. It is believed 
that one complete cell cycle comprises the following stages: G1- an initial resting phase; 
S- the synthetic phase, during which the doubling of the DNA occurs; G2- a second 
resting phase or premitotic phase; and M- the actual process of mitosis (Campbell et al. 
1990). 
Cells die by two primary processes: A) necrosis, in which the release of 
intracellular proteases and lysozymes results in an inflammatory response, or B) 
apoptosis, a programmed cell death process, which is an active, genetically regulated 
process of cell suicide. Apoptosis is characterized by specific morphological changes 
including cell shrinkage, loss of contacts, condensation, and segregation of chromatin 
around the nuclear membrane. In contrast to necrosis, apoptosis does not cause 
inflammation (Farkas et al. 2001, Israels et al. 1999, Hale et al. 1996). The major 
mechanism of cell removal is believed to be apoptosis. Normal apoptotic cell removal 
and cell replacement in tissue are estimated at 1xl011 cells per day- equivalent to the 
turnover of an adult's total body weight every 18 to 24 months (Israels et al. 1999). 
Although the underlying mechanism(s) of apoptosis are not fully understood, it is 
believed that apoptosis occurs in a multi-step process and is regulated by genes such as 
p53 gene, bcl-2/bax gene family, protease, c-myc, c-fun and/or endonuclease depending 
on cellular development context or cell type (Parton et al. 2001, Ellis et al. 1998, Ferreira 
2 
et al. 1999, Bergh 1999, Hamilton et al. 2000, Kumar 1997, Raff 1998, Jehn et al. 1997). 
For instance, p53 regulatory gene can induce cell cycle arrest in G1 or it can promote 
apoptosis. If cell damage is considered repairable, p53-induced cell cycle will allow time 
for DNA repair. With more extensive damage, p53 will signal cell to undergo apoptosis 
pathway. Although apoptosis is regulated by gene expression, it can be triggered by 
genotoxic damage, such as chemotherapy and radiation, or deprivation of cytokines such 
as erythropoietin (Ehlert et al. 2001, Kaufmann et al. 2000, Mendenhall et al. 2002). 
It was found that specific neoplastic cells exhibit abnormal patterns of 
differentiation (Waxman et al. 1991, 1996). The therapy that can induce cancer cell 
differentiation is referred to as differentiation therapy. Differentiation therapy has drawn 
much attention recently since it is less toxic and more selective compared with 
conventional chemotherapy. Differentiation therapy is based on that the abnormality of 
cancer cells can be killed by differentiation inducers which can result in tumor 
reprogramming, in a loss in proliferating capacity and induction of terminal 
differentiation (Ebert et al. 1994, Jiang et al. 1994). Over the last decade, differentiation 
agents have been successfully used in the treatment of leukemia. Among the drugs that 
can induce the differentiation in cancer cells, all-trans retinoic acid is the first and most 
effective one used for the treatment of acute promyelocytic leukemia (APL) (Huang et al. 
1988, Warrell et al. 1993). Studies show that treatment by differentiation drugs also 
resulted in the apoptosis of leukemic cells (Gianni et al. 2000). 
Many approaches have been used to treat cancer, such as surgery (De la Habra 
Rodriguez et al. 2002), radiotherapy (Mendenhall et al. 2002, Weichselbaum et al. 2001), 
3 
chemotherapy (Goodman 2000), immunotherapy (Haviv et al. 2001, Jaffar et al. 2001, 
Scollay 2001), gene therapy (Idowu 2001), photodynamic therapy (Bown et al. 1002, 
Dima et al. 1998) and hormonal therapy (Krauss et al. 2002). The most commonly used 
treatment involves the removal of a tumor by surgery or radiation therapy, combined with 
chemotherapy that may eradicate micro-tumor. Although biological treatments such as 
gene therapy and immunotherapy have recently attracted attention, they still cannot 
replace other treatments, especially chemotherapy. Chemotherapy has played and will 
continue to play an important role in cancer treatment. 
There are many chemotherapeutic anticancer drugs available, which act at 
specific phases of the cell cycle and some of them are summarized in Figure 1.1. 
The currently available anticancer drugs can be classified into several major 
groups according to their structures and/or mechanisms of action, such as alkylating 
agents, antimetabolites and natural products, etc. Within each category, drugs may be 
further classified into various sub-groups. For example, antimetabolites can be divided as 
cytidine analogues, purine analogues, pyrimidine analogues and others. Some of the anti-
cancer drugs are shown in Figure 1.2. 
Alkylating agents were among the first anticancer drugs and examples include 
nitrogen mustards, mechlorethamine and tris(P-chloroethyl)amine. This class of drugs 
acts through the covalent bonding of alkyl groups to a number of nucleophilic groups 
such as amino, carboxyl, sulfhydryl or imidazoles moieties in proteins and nucleic acids 
and forrn the alkylated products. 
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Figure 1.1. Chronology of the development of some of the anticancer drugs, taken from 
Baguley 2002. N Mustard stands for nitrogen mustard, and Cytarabin and BCNU 
represent cytosine arabinoside and bischloroethylnitrosourea, respectively. 
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Figure 1.2. Structures of some anticancer drugs 
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Most antimetabolites destroy cancer cells by interfering with nucleic acid 
synthesis or nucleotide synthesis. Many antimetabolites are nucleoside analogues 
(Baguley 2002, Manfredini et al. 1997). Nucleosides are fundamental components in 
nucleic acid synthesis. Nucleoside analogues upon being taken up by cancer cells 
interfere with nucleoside and nucleotide synthesis and metabolism of cancer cells, thus 
resulting in growth inhibition of cancer cells (Daher et al. 1990). Cytidine analogues 
were originally isolated from the sponge Cryptothethya crypta. There are three major 
mechanisms of action believed to be responsible for cytidine analogues: inhibition of 
DNA polymerase alpha, incorporation into DNA, and termination of DNA chain 
elongation. The most active agent of this class is arabinosylcytosine (ara-C) which is used 
mainly in combination with doxorubicin or daunomycin for the treatment of acute 
myelocytic leukemia (Ellison et al. 1968). Purine analogues, on the other hand, inhibit de 
novo purine synthesis/purine interconversion and incorporate into DNA or RNA. 
Pyrimidines are another class of antimetabolite anticancer drugs. 5-Flurouracil (5-FU) 
and 5-fluoro-2' -deoxyuridine (FUdR) are examples of fluorinated pyrimidine analogues. 
Both of them act as anticancer drugs by inhibiting thymidylate synthetase (TS) and by 
incorporation into DNA leading to cell death. 
1.2 5-Fluoro-2' -deoxyuridine (FUdR) 
FUdR, one of the pyrimidine nucleoside analogues, is used extensively for the 
treatment of many cancers, such as colon cancer, colorectal cancer, pancreatic cancer, 
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liver cancer and breast cancer (Heidelberger et al. 1957, Nicum et al. 2000). The 
chemical structure of FUdR is shown in Figure 1.3. 
0 
HO 
OH 
Figure 1.3. The structure ofFUdR 
FUdR first undergoes phosphorylation forming 5-fluoro-2' -deoxyuridine-5'-
monophosphate (FdUMP) followed by 5-fluoro-2' -deoxyuridine-5' -diphosphate 
(FdUDP) and 5-fluoro-2' -deoxyuridine-5' -triphosphate (FdUTP). Then it interferes with 
DNA synthesis by at least two mechanisms (Mader et al. 1998, Pratt et al. 1994, Schuetz 
et al. 1984, 1986) as shown in Figure 1.4. 
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The first possible mechanism is that FdUMP, a product of the phosphorylation of 
FUdR, inhibits of thymidylate synthetase (TS) (Santi et al. 1974, Pratt et al. 1994, Mader 
et al. 1998). TS is an essential enzyme for the synthesis of 2' -deoxythymidine-5'-
monophosphate (dTMP) as shown in Figure 1.4 and inhibition of TS leads to impaired 
synthesis of thymidylate and cell death as a result of a "thymidineless state". It is 
believed that FdUMP competes with deoxyuridine monophosphate (dUMP) forTS and 
its co-factor, N-5,10-methylenetetrahydrofolate, thus inhibiting conversion of dUMP to 
dTMP and subsequently synthesisof 2'-deoxythymidine-5'-diphosphate (dTDP) and 2'-
deoxythymidine-5' -triphosphate (dTTP). Ultimately it inhibits DNA synthesis. Figure 
1.5 further illustrates the interaction of FdUMP with TS and N-5,10-
meth ylenetetrahydrofolate. 
The second possible mechanism is that FdUTP, a product of the phosphorylation 
of FUdR, acts as a substrate for DNA polymerase (Tanaka et al. 1981, Ingraham et al. 
1980), and is incorporated into DNA (Schuetz et al. 1984, 1986, Mader et al. 1998), 
particularly in the presence of decreased dTTP resulted from the above process 
(inhibition of TS). This mis-incorporation of FdUTP into DNA can change the stability of 
DNA due to the production of DNA strands which have small fragments, leading 
ultimately to cell death (Cheng and Nakayama 1983). 
9 
FUdR 
DNA 
polymerase 
FdUMP -- FdUDP- FdUTP ----
TS and its cofactor 
DNA 
FU-DNA 
FdUM~binds to 
polymerase 
dUMP X .. dTMP -- dTDP -- dTTP DNA 
Thymidylate Synthetase 
N-5, 1 0-methylenetetrahydrofolate 
Figure 1.4. Activation and mechanism of action of FUdR. This diagram was taken from 
Mader et al. 1998. 
Due to its poor bioavailability, FUdR is usually given by intra-arterial infusion 
rather than oral administration. FUdR is known to suffer from a number of problems 
including toxicity to normal tissues especially rapidly dividing tissues, such as 
gastrointerstinal mucosa and bone marrow (Hohn et al. 1985), rapid blood clearance and 
drug resistance. These problems limit FUdR's success in the clinic. Many strategies have 
been devised to enhance FUdR's clinical activity and/or minimize its toxicity. Some of 
these approaches involve a combination of FUdR with other cytotoxic agents such as 
methotrexate (Hull et al. 1988). 
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Figure 1.5. Interaction of FdUMP with TS and N-5, 10-methylenetetrahydrofolate (Santi 
et al. 1974, Sommer and Santi, 1974). 
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1.3 All-trans retinoic acid (retinoic acid) 
All-trans retinoic acid (3,7-dimethyl-9-(2,6,6-trimethyl-l-cyclohexen-l-yl)-
2,4,6,8-nonatetraenoic acid) is a polyene carboxylic acid and a derivative of retinol, also 
known as Vitamin A. Its chemical structure and related retinoid compounds are shown in 
Figure 1.6. The resemblance of this compound to a long-chain polyunsaturated fatty acid 
explains its limited aqueous solubility. Because of the existence of the conjugated 
polyene group, retinoic acid is relatively susceptible to chemical reactions, which is 
believed to attribute to its biological activity and site of action. 
All-trans retinoic acid R=COOH 
Retinal R=CHO 
Retinol (vitamin A) R=CH20H 
R 
Figure 1.6. The structures of all-trans retinoic acid and related retinoid compounds. 
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In the body, retinoic acid is generated through irreversible oxidation of retinal 
which is biosynthesized by reversible oxidation of Vitamin A (Bianer and Olson, 1994). 
The latter mainly originates from the diet and derives from provitamin A carotenoids 
from vegetables or retinyl esters from animal sources. Retinoic acid is present at low 
concentration in the blood and the rate of retinoic acid formation varies in tissues 
depending on specific need of the cell. It is believed that retinoic acid is the most active 
metabolite of Vitamin A, which plays important roles in human visual function as well as 
in controlling normal cell growth, differentiation and metabolism. 
The mechanism of entry of retinol into normal cells is not fully understood. It 
may enter cells via specific receptors for retinol-binding protein (RBP) on cell surfaces 
(Rask and Peterson 1976) as shown in Figure 1.7 or by simple diffusion of retinoic acid 
(Nay and Xu 1990). The entry of retinol into cells has at least two purposes: storage of 
retinol as retinyl esters, or undergoing metabolism to produce active metabolites, mainly 
retinoic acid, which regulates nuclear retinoid receptors after entering into the cell 
nucleus. Once retinol gets into cells, it may bind to cellular retinol-binding proteins, 
CRBP-I and CRBP-ll (Napoli et al. 1991, Fiorella et al. 1991). After retinoic acid is 
generated through enzymatic oxidation of retinol, one of the following or a combination 
would occur: binding to cellular retinoic acid binding proteins (CRABP-I and CRABP-ll), 
which would facilitate retinoic acid passing through the nuclear membrane, interacting 
with proteins such as P450 enzymes leading to inactive metabolites, or undergoing 
isomerization to 9-cis retinoic acid and/or 13-cis retinoic acid by the catalysis of 
isomerases. Although the functions of CRABPs are still not clear, it has been suggested 
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that CRABPs may regulate intracellular concentration of retinoic acid (Boylan and Gudas, 
1992), may facilitate the transport of retinoic acid to the nucleus, and may deliver retinoic 
acid to specific chromatin sites in order to regulate gene expression (Takase eta!. 1986, 
Fiorella et al. 1991). In the nucleus, retinoic acid and its isomers control gene expression 
upon binding to nuclear retinoid X receptors (RXRs) and retinoic acid receptors (RARs), 
which bind to specific DNA sequences, or response elements RARE and RXRE 
(Mangelsdorf et al. 1994). 
To date, three subtypes of retinoic acid receptors: RAR-a, -~, and -y, and three 
subtypes of retinoid X receptors: RXR-a, -~, and-y, have been characterized (Benbrook 
et al. 1988, Brand et al. 1988, Zelent et al. 1988, Chambon 1996, Mangelsdorf et al. 
1992). It has been found that retinoic acid exclusively binds to RAR receptors and 9-cis 
retinoic acid would bind to both RAR and RXR receptors. In conclusion, retinoids 
modulate cell phenotypes by binding to a number of retinoid receptors (RARs and RXRs ). 
It has been suggested that RARs may regulate the cell proliferation and differentiation, 
while RXRs may modulate cell apoptosis (Mehta et al. 1996, Boehm et al. 1997). 
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Figure 1.7. Retinoic acid signaling pathway in liver cells. Retinoic acid enters the cells 
by free diffusion or by conversion from retinol that has been absorbed from the 
gastrointestinal tract, bound in circulation to retinol-binding proteins (RBPs), and 
rebound intracellularly to cellular retinol-binding proteins (CRBPs) after entering into the 
cell. Retinoic acid can be immediately metabolized upon binding to cellular RA-binding 
proteins (CRABPs), oxidized by cytochrome P4so enzymes and/or isomerized to 9-cis 
retinoic acid and 13-cis retinoic acid. Retinoic acid nuclear receptor RAR and retinoid X 
receptor RXR upon binding to retinoic acid, 9/13-cis retinoic acid interact with specific 
DNA response elements to regulate gene expression (Warrell 1994, Mangelsdorf et al. 
1994, Agadir et al. 1999). 
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Most of the metabolites of retinoic acid have been proven to be inactive (Blaner et 
al. 1994, Curley et al. 1997) (Figure l.S). However, recent studies showed that 9-cis 
retinoic acid and 13-cis retinoic acid may have activity for regulating retinoic acid 
receptors (RAR) or retinoid X receptors (RXR) (Giguere 1994, Mangelsdorf et al. 1994). 
The pathways for their biosynthesis in vivo are unknown. The isomerization of retinoic 
acid to 9-cis retinoic acid and/or 13-cis retinoic acid could be one of in vivo pathways for 
biosynthesis of these species. In addition, isomerization of retinoic acid and 9-cis retinoic 
acid within the cell may provide a way to regulate the activity of retinoic acid. 
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Figure 1.8. The major metabolites of retinoic acid (Blaner et al. 1994, Curley et al. 1997) 
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Retinoic acid has been reported to induce in vitro malignant cell differentiation or 
to suppress cell proliferation in numerous cancer cell lines (Kizaki et al. 1994, Bollag et 
al. 1994, Muccio et al. 1998, Nay! et al. 1998). In addition, retinoic acid has been used 
clinically in cancer therapy and prevention. These include treatment of the premalignant 
lesions in oral leukoplakia (Hong et al. 1986), acute promyelocytic leukemia (APL) 
(Huang et al. 1988), and other cancers such as skin, head, breast and liver cancers 
(Hansen et al. 2000, Bollag et al. 1994, Muccio et al. 1998), with the greatest success 
treating the patients with APL. 
There is a close relationship between the expression of specific retinoid receptors 
and clinical retinoid responses, and some of them are listed below (after Nason-
Burchenal and Dmitrovsky, 1999): 
Acute promyelocytic leukemia : PMURARa 
Myeloid leukemia (HL-60): RARa 
Oral leukoplakia: RAR~ 
Breast cancer: RARa + RAR~ 
For example, the rearranged receptors PMURARa in APL cells have been credited with 
the successful treatment of APL by retinoic acid. 
The predominant side effects of retinoic acid therapy include dryness of skin and 
mucous membranes, headache, hypertriglyceridemia, bone pain, and pseudotumor cerebri, 
particularly in pediatric patients (Castaigne et al. 1990, Toh et al. 1992, Hakimian et al. 
1993). The other major side effect is the retinoic acid syndrome characterized by fever, 
respiratory distress, pulmonary infiltrates, pleuropericardial effusions, and edema after 2-
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28 days of treatment (Frankel et al. 1992). In addition, it has been observed that 
prolonged use of retinoic acid alone may result in development of drug resistance 
(Muindi et al. 1992). 
1.4 Cis-4,7,10,13,16,19-docosahexaenoic acid (DHA) 
DHA is one of the essential omega-3 unsaturated fatty acids (Conner 2000). It is 
found in marine oils in high amounts (5-15%) and also in human tissues such as brain 
gray matter, retina, nerve, heart, sperm, etc. In addition, it is found in human milk 
(Kuroda et al. 2001). The structure of DHA is shown in Figure 1.9. 
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Figure 1.9. The structure of DHA 
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Unsaturated fatty acids including DHA have been shown to have anti-
proliferation and cancer growth inhibitory properties (Plumb et al. 1993, Das l99 L Das 
and Ramesh 1998, Guffy et al. 1984, Hon·obin 1990, Jiang et al. l998a, Connolly et al. 
1999, Pascale et al. 1993). Statistics also showed that the cancer incidence is generally 
low in the Eskimos in Greenland and Alaska where people consume large amounts of oils 
derived from marine animals (Blot et al. 1975, Bang et al. 1976). Epidemiological 
studies in Swedish found that those who consumed large quantity of fish have 
significantly lower incidences of prostate cancer than those who consumed little fish in 
their diet (Terry et al. 2001). 
It has been reported that exogenous unsaturated fatty acids resulted in increased 
accumulation of anticancer drugs such as doxorubicin in cancer cells such as Ll210 
murine leukemia cell line or small-cell lung cancer cell line, which is believed to be 
responsible for the observed elevated cytotoxicity either in vitro and/or in vivo (Tan et al. 
2000, Menendez et al. 2001, Rudra et al. 2001, Germain et al. 1998, Shao et al. 1995). 
Precise mechanisms for the increased intracellular accumulation of anticancer drugs 
resulted from the use of unsaturated fatty acids have not been determined. However, it 
has been proposed that the increased accumulation of anticancer drugs inside cells could 
result from changes in biophysical properties and functions of tumor cell membranes 
brought about by fatty acid supplementation (Timmer-Bosscha et al. 1989, Zijlstra et al. 
1987, Burns and North, 1986, Jiang et al. 1998b). Membrane fluidity and drug transport 
are influenced by the compositional ratio of saturated fatty acids to unsaturated fatty 
acids: the greater the percentage of unsaturated fatty acids, the greater membrane fluidity, 
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and the greater proportion of anticancer drugs enter the cells, since many anticancer drugs 
are considered to enter the cell by passive diffusion (Avdeef 2001). 
The increased cytotoxicity observed with the use of unsaturated fatty acids has 
also been suggested to be due to the formation of peroxidation products and free radicals 
involved in the modulation of drug efficacy by fatty acids, especially by unsaturated fatty 
acids (Das 1991, Igarashi et al. 2000, Menendez et al. 2001, Sagar et al. 1992). Some 
anticancer drugs yield oxygen-reactive species that could react with the unsaturated fatty 
acids and induce the peroxidation process (Berchekroum et al. 1993). In addition, it has 
been speculated that unsaturated fatty acids may affect the protein expression related to 
cell adhesion and motility (Jiang et al. 1995a, 1998c, 1995b). It has been proven that 
DHA-induced apoptosis can be inhibited by phosphatidic acid (PA), a specific protein 
phosphatase-! (PP1) inhibitor and hence this process is considered to be mediated 
through activation of PPI (Siddiqui et al. 2001). In addition, others suggested that 
unsaturated fatty acids modulate the expression of some early genes, such as c-jun and c-
fos, which are associated with cell apoptosis (Sellmayer et al. 1997). 
1.5 Targeted drug delivery 
Although there are many drugs available for cancer chemotherapy, there are 
problems associated including drug toxicity to normal cells and development of drug 
resistance. Targeted delivery of anticancer drugs to cancer cells would reduce the toxicity 
and increase the efficacy of anticancer drugs. 
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The concept of drug targeting was first suggested by Paul Ehrlich almost a 
century ago and an idea of "magic bullets'' was proposed (Ehrlich 1906). Since then. drug 
targeting or targeted delivery has drawn a tot of attention. Theoretically, a good 
anticancer drug carrier for in vivo use should meet the following criteria (Kader 1997): 
e The drug-carrier conjugate must be stable, both during storage and in vivo. 
e The carrier should be biocompatible and biodegradable, and the drug 
conjugate must not produce unacceptable levels of toxicity or immunological 
reactions. 
• The carrier should be suitable for targeting. 
• The drug-carrier conjugate must allow release of the drug at the target site. 
• The carrier must not cause unspecific uptake by non-target cells. 
To date, a number of particulate systems have been proposed as drug carriers such 
as emulsions, microspheres, lipoproteins, nanoparticles and liposomes (Davis et al. 1986, 
Schilsky et al. 1996, Schmidt-Erfurth et al. 1994, Lundberg 1994, Filipowska et al. 1992, 
Nishioka et al. 2001, Kreuter 2001). Monoclonal antibodies have also attracted a lot of 
attention (Dubowchik and Walker 1999, Garnett 2001). In addition, cells, cell ghosts, 
and micelles have been studied as targeted drug carriers (Torchilin 2000). Recently, 
magnetic drug targeting, which is based on binding anticancer drug with ferrofluids that 
concentrate the drug in the tumor site under magnetic fields, has also been investigated 
(Lubbe et al. 2001). 
Although many drug carriers have been investigated, there are many obstacles to 
the successful delivery of drugs using these carriers, such as rapid clearance by the 
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reticulo-endothelial system (RES) resulting in low plasma half-life and instability of the 
carrier-drug conjugates in vivo (Kader et al. 1998). Low density lipoprotein (LDL) has 
been proposed and studied as a carrier for cytotoxic agents recently (De Smidt et al. 1990, 
Shaw et al. 1987, Counsell and Pohland 1982). LDL is a quasispherical endogenous 
nanopartical with a long serum half life of 2-4 days. Over the past several years our 
group has investigated the potential of using LDL as a drug carrier for anti-cancer drugs. 
1.6 LDL as a carrier for cytotoxic agents 
Lipoproteins are complexes that serve to transport cholesterol and triglycerides in 
the blood stream. According to their buoyant density, plasma lipoproteins are classified 
into four major groups called chylomicrons (CM), very low density lipoprotein (VLDL), 
LDL and high density lipoprotein (HDL) (Bradley et al. 1978). CM and VLDL are the 
largest and lightest of lipoproteins and are the major carriers for triglycerides. LDL and 
HDL contain cholesterol esters as the predominant lipid. In man, LDL cholesterol 
contributes about two-thirds of the circulating plasma cholesterol, which is a major 
constituent of the mammalian cell membrane. 
Figure 1.10 shows the schematic structure of LDL. LDL is a spherical particle 
with a diameter of approximately 22 nm and a mass of over 1 x 106 daltons. LDL 
contains a hydrophobic core of approximately 1500 molecules of cholesteryl ester. It is 
shielded from the aqueous blood by an amphiphilic shell that consists of monolayer of 
phospholipids, free cholesterol as well as proteins known as apoproteins. The cholesterol 
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on the surface can exchange rapidly with cholesterol in other structures such as cellular 
membranes, whereas the cholesteryl ester molecules remain more firmly in the oily core 
(Firestone 1994, Van Berkel 1993, Kader et al. 1998). 
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Figure 1.10. The schematic structure of LDL 
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Apoprotein on the surface of the LDL phospholipid monolayer is a single 
514,000-dalton protein called apoprotein B (Apo-B). Apo-B is recognized by specific 
cell surface receptors, i.e., LDL receptors, which carry LDL into the cell by receptor-
mediated endocytosis. Figure 1.11 shows the fate of LDL particles and LDL receptors 
after endocytosis. 
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Figure 1.11. Fate of LDL particles and LDL receptors after endocytosis. After binding of 
LDL to the LDL receptor, the lipoprotein is internalized and delivered to the lysosomes, 
where the cholesteryl esters can be hydrolyzed. Liberated cholesterol can pass the 
lysosomal membrane and is available for cellular metabolism, such as formation of 
membranes or steroids (De Smidt et al. 1990, Counsell et al. 1982). 
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After a LDL particle binds to the LDL receptor, the receptor-ligand complex is 
internalized in a coated pit by endocytosis, where the lower pH causes the dissolution of 
LDL from its receptor. In a subsequent step, the LDL dissociates from the receptor and 
the receptor is transported back to the plasma membrane. The endosome containing LDL 
now fuses with lysosomes, forming a large secondary lysosome. In this lysosome the 
apoprotein B is degrac;led into amino acids by proteases, and the cholesteryl esters are 
hydrolyzed to fatty acids and cholesterol by lipases, and cholesterol is available for the 
cellular metabolism such as formation of membranes or as the precursor for the 
biosynthesis of steroids (Figure 1.11 ). Excess amounts of cholesterol can be re-esterified 
into CE and stored as oil droplets for future use. 
Interest in LDL as a drug carrier has been triggered by the discovery that many 
cancer cells show a high receptor-mediated uptake of LDL (Ho, et al. 1978, Tokui et al. 
1995, Maletinska et al. 2000). The high levels of LDL receptors present on the surface of 
cancer cells may be explained by the fact that cancer cells presumably need more 
cholesterol because of the fast dividing nature of cancer cells. The increased need for the 
formation of new membrane material is met by the increased LDL uptake from the blood 
circulation. Thus, if LDL can be an anticancer drug carrier, it might serve as a targeting 
carrier. It has been shown that cancer cells are associated with elevated levels of LDL 
receptors (Vito! et al. 1985, Rudling et al. 1986, 1990). LDL could deliver anticancer 
drugs more specifically to cancer cells. The concern of using LDL. as a drug carrier for 
anticancer drugs is the significant dumping of anticancer drugs to normal tissues where 
high levels of LDL receptors exist such as liver. However, it has been demonstrated that 
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the level of LDL receptors in those tissues can be effectively down-regulated. For 
example, the LDL receptor in the liver can be successfully lowered by. means of dietary 
fats, cholesterol and bile salts (Dietschy et al. 1986). 
Furthermore, LDL lacks immunogenicity (Filipowska et al. 1992, Van Berkel 
1993), which is an advantage over many foreign particles. Its native structure has a lipid 
droplet that maybe used to store lipid soluble drugs (Firestone 1994). 
1. 7 Design of prodrugs 
LDL appears to be a good drug carrier for delivering anticancer drugs since 
cancer cells have higher LDL receptor levels than normal cells. However, due to the high 
hydrophilicity of FUdR, it is expected to be difficult to incorporate it into LDL which is 
rather hydrophobic. Therefore, chemical modification or preparation of prodrugs is 
necessary to increase the hydrophobicity of FUd.R. To increase hydrophobicity, 
esterification is usually the first choice, since esters are easily hydrolyzed by esterases 
which are rich in the human body (Bundgaard 1991). Given the chemical structure of 
FUdR (with two hydroxyl groups), it is possible to design an ester which is more 
hydrophobic. With the increased lipophilicity, the prodrug is expected to be easily 
incorporated into the LDL carrier. 
Although many esters of FUdR have been reported in literature (Schwendener et 
al. 1985, Kawaguchi et al. 1988, Yamashita et al. 1988, Halmos et al. 1992), we decided 
to prepare retinoyl and DHA derivatives of FUd.R. There is evidence of interesting 
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synergistic or additive antitumor effects by simple physical combination of retinoic acid 
with other anticancer drugs such as cytosine arabinoside (Hassan et al. 1986, Chomience 
et al. 1986, Ponzoni et al. 1991, Li eta!. 1997, Nudelman and Rephaeli 2000). Therefore, 
the retinoyl derivative of FUdR or DHA derivative of FUdR have the potential to display 
increased lipophilicity and also improved efficacy, since retinoic acid or DHA will be 
released in addition to FUdR upon hydrolysis of the respective prodrugs. In addition, 
retinoic acid and DHA function via different mechanisms which may result in synergistic 
effect. It has been proved that some retinoic acid prodrugs are more effective inducers of 
cell differentiation and/or apoptosis in a number of neoplasias (Formelli et al. 1996, 
Manfredini et al. 1997). 
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Chapter 2 Objectives 
The objectives of this research project are as follows: 
1. to design and synthesize novel prodrugs of FUdR, 
2. to incorporate the proposed prodrugs into LDL, a drug carrier, 
3. to evaluate and compare the cytotoxicity of the proposed prodrugs, prodrugs/LDL 
with that of FUdR. 
The novel prodrugs designed for this project were the retinoic acid and DHA 
conjugates of FUdR as shown in Figure 2.1 based on the following reasons: 
• With retinoic acid or DHA conjugated to FUdR, it is anticipated that the resultant 
compounds will possess an enhanced lipophilicity which is essential for the 
incorporation into the proposed drug carrier, LDL. 
• As discussed earlier in the Introduction, both retinoic acid and DHA have been 
proven to be beneficial against cancer. The two species (retinoic acid and FUdR or 
DHA and FUdR) released upon hydrolysis of the derivatives will be active via 
different mechanisms. 
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5' ,5' -di-0-retinoyl-FUdR (Compound 4) 
-CzoH270 -CzoH210 
5' -0-retinoyl-FUdR (Compound 11) 
-CzoH270 H 
3'-0-retinoyl-FUdR (Compound 7) H -CzoHz70 
3' -0-DHA-FUdR (Compound 13) H -CzzH310 
Figure 2.1. The chemical structures of the proposed FUdR prodrugs 
The prodrugs synthesized were incorporated into LDL, a tumor seeking carrier, 
forming prodrug/LDL complexes. 
The following studies were carried out to evaluate the prodrugs and 
prodrugs/LDL in comparison with FUdR. 
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• Cytotoxicity using MTI assay in two human breast cancer cell lines: MB231 and 
MCF7, one cervical cancer cell line: Hela, and one hepatic cancer cell line: HepG2. 
• Differentiation effect of these prodrugs against leukemia cell line: CEMff -1-. 
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Chapter 3 Materials and Methods 
3.1 Materials 
FUdR, retinoic acid, DHA, 4-(dimethylamino)pyridine (DMAP), and all other 
chemicals used in synthesis were purchased from Sigma-Aldrich Chemical Co and were 
of chemical grade unless otherwise specified. All chemicals were used without further 
purification unless otherwise noted. Benzene, dichloromethane (CHzClz), and 
triethylamine (TEA) were freshly distilled from calcium hydride prior to use. 
Tetrahydrofuran (THF) was distilled from sodium in the presence of benzophenone prior 
to use. 
All reactions were conducted under argon or nitrogen atmosphere protected from 
light. Unless otherwise noted, organic extracts were dried with sodium sulfate (NazS04), 
filtered through a fritted glass funnel and concentrated to dryness under reduced pressure 
(20-30 mmHg) with a rotary evaporator below 30 °C. Thin layer chromatography (TLC) 
was performed using Silica Gel 60 F254 (Fisher chemical Company). Silica Gel 60 (230-
400 mesh) was used for flash chromatography (Still et al. 1978). Nucleoside derivatives 
were examined under UV light and unsaturated fatty acid was located by exposure to 
iodine vapor. Proton nuclear magnetic resonance spectra eH NMR) were determined at 
300 MHz or 500 MHz and CDCh or DMSO-t4l was used as solvent. FAB Mass spectra 
(MS) were obtained at the Department of Fisheries and Oceans, Newfoundland. 
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All solvents used for HPLC analyses were of HPLC grade. All reagents used for 
in vitro tests were of ceiJ culture grade. 3-(4,5-Dimethyliazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) were purchased from Sigma-Aldrich Chemical 
Company. Nitro blue tetrazolium (NBT) and phorbol 12-myristate 13-acetate (PMA) 
were kindly provided by Dr. Alan Pater (Faculty of Medicine, Memorial University of 
Newfoundland). Fetal bovine serum (PBS) was purchased from GIBCO BRL Co. RPMI-
1640 culture medium, Dulbecco's modified Eagle's minimal essential medium (DMEM), 
non-essential amino acids and penicillin/streptomycin were purchased from Sigma 
biochem Co. HPLC analyses were conducted using an HP 1100 chromatographic system, 
with a CIS reverse-phase column (150 x 3.9 mm, Phenomenex). 
Fresh human plasma was obtained from the Canadian Blood Services, St. John's, 
Newfoundland, Canada. 
Human cancer cell lines, MCF7 and MB231, and cervical cell line, Hela, were 
obtained from the American Type Culture Collection (Manassas, VA, USA). Leukemia 
cell line, CEM!f4, and Hepatic Cancer cell line, HepG2, were kindly provided by Dr. 
Alan Pater (Faculty of Medicine, Memorial University of Newfoundland). 
3.2 Chemical synthesis 
3.2.1 Synthesis of retinoyl chloride (Compound 2) 
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The reaction of retinoic acid with oxalyl chloride at ambient temperature resulted 
in retinoyl chloride. Due to its instability, retinoyl chloride produced as such was used 
for the subsequent reaction without being separated from the reaction mixture. 
3.2.2 Synthesis of 3', 5' -di-0-retinoyl-FUdR (Compound 4) 
Retinoyl chloride (2) generated above reacted with FUdR at a molar ratio of 1:2 
using DMAP as a catalyst to obtain 3', 5' -di-0-retinoyl-FUdR, which appeared as a 
yellow solid as shown in Scheme 3.1. 
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Scheme 3.1. Synthesis of 3', 5' -di-0-retinoyl-FUdR 
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3 .2.3 Synthesis of 5 '-0-tiiphenylmeth yl-FUdR (Compound 5), 3 '-0-retinoyl-5 '-0-
triphenylmethyl-FUdR (Compound 6), and 3' -0-retinoyi-FUdR (Compound 7) 
FUdR possesses two hydroxyl groups on its sugar moiety with 5' -OH (primary 
alcohol) being more reactive than 3 '-OH (secondary alcohol). In order to prepare 5' -0-
retinoyl-FUdR, we first tried to condense FUdR with retinoyl chloride as with the 
preparation of 3', 5'-di-0-retinoyi-FUdR as shown in Scheme 3.1 with exception of a 
molar ratio of 1:1 (retinoyl chloride:FUdR). However, the chemical yield of 5' -0-
retinoyl-FUdR was less than 10%. The major product was still 3', 5' -di-0-retinoyl-
FUdR and the amount of 3'-0-retinoyl-FUdR was undetectable. It was then concluded 
that protection of 5' -OH or 3' -OH was necessary in order to obtain 3' -0-retinoyl-FUdR 
or 5' -0-retinoyl-FUdR. 
To prepare 3' -0-retinoyl-FUdR, FUdR was treated with chlorotriphenylmethane 
in the presence of triethylamine and DMAP (Chaudary et al. 1979) to obtain mainly 5'-
0-triphenylmethyl-FUdR (5) which was then allowed to react with retinoyl chloride to 
afford 3' -0-retinoyl-5' -0-triphenylmethyl-FUdR (Compound 6). The latter was 
hydrolyzed with 88% formic acid (Bessodes et al. 1986) to yield 3' -0-retinoyl-FUdR. 
3.2.4 Synthesis of 3' -0-tert-butyldimethylsilyl-5' -0-triphenylmethyl-FUdR 
(Compound 8), 3' -0-tert-butyldimethylsilyl-FUdR (Compound 9), 3 '-0-tert-
butyldimethylsily!-5' -0-retinoyl-FUdR (Compound 10), and 5' -0-retinoyl-FUdR 
(Compound 11) 
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Since 5' -OH is more reactive than 3' -OH, introducing the second protective group 
was deemed necessary for the preparation of 5' -0-retinoyl-FUdR and a two-step 
protection as shown in Scheme 3.3 was employed. 5' -0-Triphenylmethyl-FUdR prepared 
as above was first treated with tert-butyldimethylsilyl chloride in the presence of 
imidazole to obtain 5' -0-triphenylmethyl-3' -0-silylated FUdR (Compound 8). The 
triphenylmethyl group at the 5' -position was removed with 88 % formic acid resulting in 
3' -0-tert-butyldimethylsilyl-FUdR (Compound 9). Next, reaction of retinoyl chloride 
with compound 9 resulted in 5' -0-retinoyl-3' -0-butyldimethylsilyl-FUdR (Compound 
10). Removal of the silyl group with anhydrous tetrabutylammonium fluoride (TBAF) 
yielded 5' -0-retinoyl-FUdR. 
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3.2.5 Synthesis of 3'-0-DHA-5'-0-triphenylmethyi-FUdR (Compound 12) and 3'-0-
DHA-FUdR (Compound 13) 
To prepare 3 '-0-DHA-FUdR, FUdR was treated with chlorotriphenylmethane in 
the presence of triethylamine and DMAP (Chaudary et al. 1979) to obtain mainly 5' -0-
triphenylmethyl-FUdR (5) which was then allowed to react with DHA in the presence of 
DMAP to afford 3' -0-DHA-5' -0-triphenylmethyl-FUdR (Compound 12). The latter was 
hydrolyzed with 88 % formic acid (Bessodes et al. 1986) to yield 3' -0-DHA-FUdR as 
shown in Scheme 3.4. 
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3.3 Isolation of LDL from human plasma 
Human LDL (density 1.020-1.063 g/mL) was isolated by ultracentrifugation of 
fresh human plasma according to a published method (Schumaker et al. 1986). Briefly, 
phenylmethylsulfonylfiuoride (PMSF) was added to the fresh human plasma obtained 
from the Canadian Blood Services (St. John's, Newfoundland) up to 0.015 % in a final 
concentration as a protease inhibitor to prevent the degradation of plasma proteins. 
Potassium bromide (KBr) was used to adjust the density of plasma to 1.020 g/mL. The 
plasma was then centrifuged at 4 oc at 40,000 rpm for 24 h using a Beckman L8-M 
ultracentrifuge and a 60 Ti or 75 Ti rotor. After centrifugation, VLDL that floated to the 
top of the centrifuge tubes as a white layer was removed carefully using a disposable 
plastic pipette. The rest of the plasma was re-suspended and the density was adjusted to 
1.063 g/mL again using KBr. The mixture was then subjected to centrifugation at 40,000 
rpm at 4 oc for 24 h. LDL floated to the top of the centrifuge tubes as a yellow layer was 
collected carefully using a disposable plastic pipette. The collected LDL was dialyzed 
overnight at 4 oc against a dialysis buffer containing 0.3 mM EDTA, 150 m1\1 NaCl, and 
50 mM Tris (pH 7.4) to remove KBr. LDL after dialysis was sterilized by filtration 
through a sterile 0.20 Jlm Coming® syringe filter and was stored at -20 oc in autoclaved 
1.5 mL Eppendorf tubes. 
3.4.1 Determination of the protein concentration in LDL preparations 
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The protein concentration of the LDL preparations was determined u·sing the 
method of Bradford (Bradford 1976) with bovine serum albumin (BSA) as standard. Bio-
Rad Protein Assay Dye Reagent Concentrate was diluted 5 times in saline prior to use. 
Briefly, four standard BSA solutions in saline, 0.05, 0.1, 0.2 and 0.4 mg/mL, were 
prepared and stored in 1.5 mL autoclaved Eppendorf tubes. The LDL isolated above was 
diluted 10 times in saline prior to the assay. The assay was preformed in a 96-well 
microtitre plate. Ten J.1L of the standard BSA solutions and the diluted LDL solution were 
pipetted in quadruplicate into a 96-well microtitre plate. To these protein solutions was 
added 200 J.LL of the diluted dye reagent. The contents were mixed by vortexing for 5 
min. Immediately after vortexing, the absorbance at 595 nm was measured on a Bio-Rad 
Model 550 microplate reader interfaced with an EM PaC 386 computer. The standard 
curve was constructed by plotting the absorbance versus the concentration of the standard 
BSA solutions. The protein concentration of the LDL preparation was then determined 
using the standard curve. 
3.5 Incorporation of the prodrugs into LDL 
3.5.1 Preparation of 3'-0-retinoyl-FUdR, 5'-0-retinoyl-FUdR, 3'-0-DHA-FUdR and 
3' ,5' -di-0-retinoyl-FUdR microemulsions 
The 3' -0-retinoyl-FUdR microemulsion, 5' -0-retinoyl-FUdR microemulsion, 3'-
0-DHA-FUdR microemulsion and 3' ,5' -di-0-retinoyl-FUdR microemulsion were 
prepared using the method previously developed in our lab (Xiao et al. 1999) with minor 
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modification. Briefly, L-a-phosphatidylcholine dipalmitoyl (DPPC) ( 12 mg), DL-a-
phosphatidylethanolamine dipalmitoyl (DPPE) (10 mg), seal oil (20 mg), and lO mg of 
the respective compound (3' -0-retinoyl-FUdR, 5' -0-retinoyl-FUdR, 3' -0-DHA-FUdR 
or 3' ,5' -di-0-retinoyl-FUdR) were dissolved in 10 mL of chloroform. The chloroform 
solution was dried with a gentle stream of nitrogen. The residue was re-suspended in 10 
mL of saline. The suspension was sonicated for 2 h with a Virosonic Cell Disrupter 
Model 16-850 at 40-50 watts while being kept in salt-ice bath (-10 °C) under a nitrogen 
stream. The mixture was then subjected to ultracentrifugation at 40,000 rpm for 7-8 h at 4 
°C using a Beckman L8-M ultracentrifuge with a 60 Ti or 75 Ti rotor. The 
microemulsion floated to the top of centrifuge tubes was collected carefully by a 
disposable plastic pipette and was stored at -20 °C in 1.5 mL Eppendorf tubes. 
3.5.2 Incorporation of the prodrug 3' -0-retinoyl-FUdR, 5' -0-retinoyl-FUdR, 3' -0-
DHA-FUdR and 3' ,5' -di-0-retinoyl-FUdR into LDL 
The respective microemulsions (3' -0-retinoyl-FUdR, 5' -0-retinoyl-FUdR, 3' -0-
DHA-FUdR and 3' ,5' -di-0-retinoyl-FUdR) obtained above were incubated with the LDL 
preparation at 37 °C for 7-8 h at a molar ratio of 1000:1 (prodrug to LDL). The LDL 
loaded with 3'-0-retinoyl-FUdR, 5'-0-retinoyl-FUdR, 3'-0-DHA-FUdR or 3',5'-di-0-
retinoyl-FUdR was then separated by ultracentrifugation at 40,000 rpm for 24 h at 4 °C 
using a Beckman L8-M ultracentrifuge with a Beckman 60 Ti or 75 Ti rotor. The LDL 
layer spun down to the bottom of centrifuge tubes was collected carefully and sterilized 
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using a sterile 0.20 f.!m Coming® syringe filter. The LDUprodrug preparation was stored 
in autoclaved 1.5 mL Eppendorf tubes at -20 °C. 
3.6 Determination of the prodrug concentration in the prodrug!LDL complex 
The respective prodrugs (3'-0-retinoyl-FUdR, 5'-0-retinoyl-FUdR, 3', 5'-di-0-
retinoyl-FUdR and 3' -0-DHA-FUdR) in the prodrug!LDL complexes were first extracted 
with chloroform. Briefly, 1 mL of CHC13 was added in a 1.5 mL Eppendorf tube 
containing 50 flL of prodrug!LDL complex. The contents were mixed by vortexing for 2-
3 min. The chloroform layer was then spun down by centrifugation using an Eppendorf® 
tabletop centrifuge at 5,000 rpm for 3 min. The LDL layer floated to the top was pipetted 
and transferred to an Eppendorf tube and then extracted with chloroform two more times 
in order to extract as much prodrug as possible. The chloroform extracts were combined 
and dried under a gentle stream of nitrogen. The residue was re-dissolved in 50 f.!L of 
chloroform. HPLC analysis was performed by injecting 10 flL of the sample. The 
concentration of 3' -0-retinoyl-FUdR, 5' -0-retinoyl-FUdR, 3', 5' -di-0-retinoyl-FUdR 
and 3'-0-DHA-FUdR was then determined using an HP® 1100 HPLC with a 
Phenomenex® C18 reverse phase column (15 em x 3.9 mm, particle size 5 f.!m). 
Methanol/H20 (9/1, v/v) at 1.0 rnUmin was used as the mobile phase with UV detection 
at 267 nm. 
The standard prodrug solutions (0.2 mg/mL, 0.4 mg/mL, 0.8 mg/mL, and 1.6 
mg/mL) were prepared in chloroform. HPLC analysis was performed by injecting 10 f.!L 
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of each sample with methanoi/H20 (9/1, v/v) at 1.0 rnUmin as the mobile phase and UV 
detection at 267 nm. The area under the curve of the respective peak was calculated. The 
analysis for each sample was repeated three times. A standard curve was obtained by 
plotting the concentrations of the standard samples versus the corresponding peak area. 
The analysis was repeated three times for each sample and the results were expressed as 
the average of three analysis. The standard curve was used to determine the concentration 
of prodrug in the prodrug/LDL complexes. 
3. 7 Preparation of prodrugs in ethanol and FUd.R in PBS stock solutions 
Twenty mM of 3'-0-retinoyl-FUd.R, 5'-0-retinoyl-FUd.R, 3'-0-DHA-FUdR and 
3' ,5' -di-0-retinoyl-FUdR were prepared in 99.9% ethanol as stock solution. FUd.R (20 
mM) was prepared in phosphate-buffered saline (PBS) (2.67 mM KCl, 1.47 mM 
KHzP04, 138 mM NaCl and 8.10 mM NaHP04•7HzO). PBS was freshly prepared and 
autoclaved prior to use. The stock solutions were then sterilized using a sterile 0.20 Jlm 
Coming® syringe filter and stored at -20°C in 1.5 mL autoclaved Eppendorf tubes. The 
working solutions were obtained by diluting the stock solutions in DMEM or RPMI-1640 
medium to the appropriate concentration prior to use. In no case throughout the 
experimental assays did the final ethanol concentration of the prodrugslethanol working 
solution exceed 3 % or did the final LDL protein concentration of the prodrugs/LDL 
working solution exceed 0.35 mg/mL. 
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3.8 Cell culture 
Five cancer cell lines which contain different levels of LDL receptors were used 
in this study: two human breast cancer cell lines, MCF7 and MB231, one human cervical 
cancer cell line, Hela, one human hepatic cancer cell line, HepG2, and one leukemia 
cancer cell line, CEMIT4. These cancer cell lines were grown in a 25 cm2 Coming® flask 
at 37 oc in a humidified incubator with an atmosphere of 5% C02• MCF-7, MB231, 
HepG2 and Hela cells were maintained as monolayer in DMEM medium supplemented 
with 10% FBS, 1% non-essential amino acids, 2 mM L-glutamin, 50 IU penicillin/mL 
and 50 J.tg/rnL streptomycin. CEMIT4 cells were cultured in suspension in RPMI-1640 
medium supplemented with 10% FBS. 
These cancer cell lines were cultured according to the routine culture procedure. 
During subculturing, the suspension of CEMff4 cells in a 4 rnL medium in a 25 cm2 
Coming® flask were transferred into a 15 rnL conical centrifuge tube. CEMIT4 cells 
were harvested by centrifugation using a Thermo IEC tabletop centrifuge at 1200 rpm for 
5 min. The medium layer was then carefully removed by a sterile pipette. The cell pellet 
was re-suspended in 12 rnL DMEM medium and transferred 3 or 4 rnL into 25 cm2 
Coming® flask for subculturing. The doubling time for CEM!f4 cell was 40 h under 
these conditions. The medium was changed every two days to maintain cell growth. 
MCF-7, MB231, HepG2 and Hela cells were attached on the bottom of a 25 cm2 
Coming® flask during culture. Trypsin-EDT A solution was used to detach the cells from 
a flask. Briefly, the medium was removed upon the cells reached subconfluence, and the 
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cell monolayer was washed with 10 mL PBS. After removal of PBS, the 3 mL trypsin-
EDT A solution was added to the flask. The flask was then placed back into a humidified 
incubator \Vith an atmosphere of 5% C02 at 37 oc for 5 min in order to detach the cells 
from the flask. The cells suspension in the trypsin-EDT A solution was transferred into a 
15 mL centrifuge tube and the trypsin-EDT A solution was removed by centtifugation at 
1,200 rpm for 5 min as described previously. The cells pellet was re-suspended with 10 
mL PBS in order to remove as much trypsin-EDTA solution as possible. Once PBS 
solution was removed by centrifugation, the cell pellet was re-suspended in 12 mL 
medium. The cell suspension was then reseeded into 3-4 flasks. Under these conditions, 
the doubling times for MB231, MCF-7, Hela and HepG2 cells were 35, 30, 48 and 17 h, 
respectively. During normal culture, the medium in a flask was changed every two days. 
3.9 Assessment of cytotoxicity using Tetrazolium (MTT) assay 
Cytotoxicity test was performed using a MTT assay as described by Carimichael 
(Carmichael et al. 1987, Mosmann 1983, Li et al. 1999) with minor modification. This 
assay is based on the reduction of MTT to a colored formazen product by mitochondrial 
dehydrogenase present only in living, metabolically active cells. A 10 mg/mL stock MTT 
solution was prepared in PBS. The stock MTT solution was filtered using a sterile 0.20 
!J.m Coming® syringe filter to remove any insoluble residue and stored at 4 oc in a 
autoclaved 15 mL centrifuge tube. The MTT working solution (1.0 mg/mL) was prepared 
by diluting the stock solution in PBS prior to use. 
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Since the prodrug solution was prepared in ethanol, the cytotoxicity of ethanol 
was assessed in Hela, MCF7, MB23l and HepG2 cell lines, respectively, to ensure that 
the amount of ethanol used was not toxic and all cell death observed with the 
prodrug/ethanol solutions was attributed to prodrug alone. In addition, the cytotoxicity of 
LDL alone was also determined. Briefly, 104 cells/100 J.LUwell of cell suspension in 
DMEM were plated in quadruplicate into a 96-well microtitre plate and were kept at 37 
°C in a 5% COz humidified incubator for 24 h. The medium was then removed and 
replaced with 100 J.LL medium containing 1.5%, 3% and 6% of ethanol or 100 J.1L 
medium containing 0.125 mg/mL, 0.25 mg/mL and 0.50 mg/mL of LDL. (protein 
concentration of LDL). The plate was returned to the incubator for 72 h. Cells in DMEM 
were also cultured under the same conditions as control. At the end of 72 h, the culture 
medium was removed, and 100 f.lL of a 1.0 mg/mL MTT solution in PBS was added to 
each well and the plate was returned to the incubator for another 4 h. The supernatant 
was then removed by aspiration and 100 f.lL dimethyl sulfoxide (DMSO) was added to 
dissolve the forrnazan crystals. The plate was placed on a plate shaker for 10 min at room 
temperature to ensure that all the crystals had been dissolved in DMSO. The absorbance 
was recorded on a Bio-Rad Model 550 microplate reader interfaced with an EM PaC 386 
computer at 570 nm using DMSO as a blank measured at 630 nm. Data analysis was 
carried out using the Bio-Rad Microplate Manager®/ PC version 4 software program. 
Tests were repeated at least twice at different times for each cell line. 
The cytotoxicity of 3' ,5' -di-0-retinoyl-FUdR/LDL, 3' -0-retinoyl-FUdR/LDL and 
5' -0-retinoyl-FUdRILDL in Hela cell line and the cytotoxicity of 3' -0-retinoyl-
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FUdRILDL and 3'-0-DHA-FUdR/LDL in MCF7 and MB231 cell lines were also 
performed using the MTT assay. The respective prodrug/LDL working solutions were 
prepared by diluting the prodrug!LDL prepared as described in Section 3.5 in D.MEM to 
appropriate concentrations (8-10 concentrations of the prodrugs were tested, with the 
highest concentration being between 380 J.!M and 190 J.!M, depending on the individual 
prodrug/LDL, from which 7-9 serial 1:1 dilutions were made). Briefly, 104 cells/100 
J.!Uwell of cell suspension in DMEM was seeded in quadruplicate into 96-well microtitre 
plates and incubated at 37 °C in a 5% C02 humidified incubator for 24 h. The medium 
was then removed and replaced with 100 J.!L medium containing appropriate 
concentrations of the prodrug!LDL (8-10 concentrations as described earlier). The plates 
were returned to the incubator for 24 h, 48 h or 72 h, respectively. Cells in the presence 
of cultural medium only (without the prodrug/LDL treatment) and medium containing no 
cells were cultured under the same conditions. At the end of each time interval (24, 48 or 
72 h), the culture medium was removed, and 100 J.!L of a 1.0 mg/mL MTT solution in 
PBS was added to each well. After additional 4 h incubation at 37 °C, the supernatant 
was removed by aspiration and 100 J.!L of DMSO was added to dissolve the formazan 
crystals. The plates were then placed on a plate shaker for 10 min at room temperature to 
ensure that all the crystals have been dissolved in DMSO. The absorbance was recorded 
on a Bio-Rad Model 550 microplate reader interfaced with an EM PaC 386 computer at 
570 nm using DMSO as blank measured at 630 nm. Data analysis was carried out using 
the Bio-Rad Microplate Manager®/ PC version 4 software program. Cell survival (%) 
was calculated as the fraction of drug treated samples relative to control (cells containing 
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no drug) or mean absorbance of the treated wells divided by the mean absorbance of the 
control wells x 100. The IC50 was defined as the drug concentration causing 50% 
inhibition of cell growth as compared to the untreated cells. Tests were repeated at least 
twice at different times for each cell line and each compound. 
The cytotoxicity of respective prodrugs (3',5'-di-0-retinoyl-, 3'-0-retinoyl and 
5' -0-retinoyl-FUdR, and 3' -0-DHA-FUdR) in ethanol was also performed in Hela, 
MCF7, MB231 and HepG2 cell lines using the MTT assay. The prodrugs/ethanol 
working solutions were prepared by diluting the 20 mM prodrugs/ethanol stock solution 
prepared according to Section 3.7 in DMEM medium to approximately similar 
concentration to the prodrugs!LDL working concentration. Briefly, 104 cells/100 JlUwell 
of cell suspension was plated in quadruplicate into 96-well microtitre plates. After 24 h 
seeding at 37 °C in a 5% C02 humidified incubator, the media were removed and 
replaced with 100 IlL-medium containing appropriate concentrations of prodrug/ethanol 
(8-10 concentrations). The plates were incubated for 24 h, 48 h or 72 hat 37 oc in a 5% 
C02 humidified incubator. Control cells without prodrug/ethanol treatment and blank 
wells containing medium with no cells were cultured under the same conditions. At the 
end of each time point, the culture medium was removed, and 100 J.lL of a 1.0 mg/mL 
MTT solution in PBS was added to each well. After additional 4 h incubation at 37 °C, 
the supernatant was removed by aspiration and 100 JlL DMSO was added to dissolve the 
formazan crystals. Plate was then placed on a plate shaker for 10 min at room 
temperature to ensure that all the crystals have been dissolved in DMSO. The absorbance 
was recorded on a Bio-Rad Model 550 microplate reader interfaced with an EM PaC 386 
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computer at 570 nm using DMSO as a blank measured at 630 nm. Data analysis was 
canied out using the Bio-Rad Microplate Manager®/ PC version 4 software program. 
Cell survival (%) was calculated as the fraction of cell alive relative to control (mean 
absorbance in the treated wells/mean absorbance in the control wells x 100). The IC50 
(Inhibitory Concentration 50%) was defined as the drug concentration causing 50% 
inhibition of cell growth as compared to the untreated cells. Tests were repeated at least 
twice at different times for each cell line and each compound. 
3.10 In vitro differentiation test in CEMIT4 cell line 
The differentiating activity (Balzarini et al. 1995; Manfredini et al. 1997) of 
retinoic acid, FUdR, 3' -0-retinoyl-FUdR, 3' -0-DHA-FUdR and 5' -0-retinoyl-FUdR 
was examined in leukemia cell line, CEMIT4. Briefly, the differentiation was 
characterized by superoxide production after stimulation with phorbol 12-myristate 13-
acetate (PMA). Nitro-blue tetrazolium (NBT) is a pale yellow dye that is reduced by 
superoxide to a dark blue water-insoluble fromazan. In the NBT reduction assay, 106 
CEM/T4 cells per 1.0 mL of cell suspension in RPMI-1640 culture medium were seeded 
in triplicate in a 24-well plate. One hundred JlL of the respective prodrugs in ethanol in 
various concentrations (0.01 JlM, 0.1 11M and 1 11M) was added to each well. The plates 
were then incubated for 72 h at 37 oc in a 5% C02 humidified incubator, following 
which 0.5 mL of a freshly prepared NBT solution (2.0 mUmg, containing PMA at 200 
ng/mL in PBS, pH 7.2) was added to each well. The mixture was further incubated for 40 
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min in a shaker kept in a water bath at 37 °C. The plate was cooled on ice for 5 min to 
stop the reaction. The cell suspension was transferred into 1.5 mL Eppendorf tubes. The 
cells were spun down at 1,000 rpm for 10 min at 4 °C, following which the supernatant 
was carefully removed. The cell pellet was re-suspended in 0.5 mL of RPMI-1640 
medium, kept on ice and protected from light until the percentage of cells containing dark 
blue formazan precipitates was determined in a hemocytometer under an inverted light 
microscopy. For each sample, at least a total of 200 cells were scored, and the percentage 
of formazan-positive (NBT-positive) cells was calculated. Cells alone (in the absence of 
any prodrugs) were examined and used as control. It was found that the control contained 
not more than 10% NET-positive cells. Experiments were repeated at least twice at 
different times for each compound. 
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Chapter 4 Results and Discussion 
4.1 Retinoyl chloride (Compound 2) 
To a solution of retinoic acid 1 (106 mg, 0.36 mmol) in freshly dried benzene (10 
mL) was added oxalyl chloride (46 J.!L, 0.54 mmol). The reaction mixture was stirred at 
ambient temperature and protected from light for 2 h under positive argon pressure. The 
resultant mixture (dark yellow) was then subjected to evaporation on a rotary evaporator, 
and the residue was re-dissolved in freshly dried benzene (5 mL). Retinoyl chloride was 
used immediately for the next reaction. 
4.2 3', 5'-Di-0-retinoyl-FUdR (Compound4) 
To a solution of FUdR (85.4 mg, 0.333 mmol), DMAP (85.52 mg, 0.70 mmol) in 
7 ml dry benzene, kept in an ice-bath, was added retinoyl chloride (0.667 mmol) in 5 ml 
dry benzene slowly. The reaction mixture was stirred in ice-bath for 1 h, then refluxed for 
3 h. After cooling down to the room temperature, the mixture was diluted with 30 ml 
ethyl acetate, then washed by saturated NaHC03 (2 x 20 ml), water (2 x 15 ml), and dried 
with Na2S04. After removal of the solvent in vacuo, the residue was chromatographed on 
a silica gel column using gradient elution (from hexanes to hexanes-ethyl acetate, 1.5:1, 
v/v) to afford 3' ,5' -di-0-retinoyl-FUdR as a yellow solid (200 mg). The Rt value was 
0.59 in ethyl acetate:hexanes 1:1.5 (v/v). The chemical yield was determined to be 72%. 
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The melting point of 3', 5' -di-0-retinoyl-FUdR was in the range of 97.5-99.5 °C. 1H 
NMR (CDCi]) data: 8 1.04 (s, 12H, 4 x cyclohexene-Me), 1.30-1.70 (m. 8H, 
cyclohexene), 1.73 (s, 6H, 2 x cyclohexene-Me), 2.02-2.23 (m, llH, H-2', retinoyl-Me, 
cyclohexene), 2.39 and 2.42 (twos, 6H total, 2 x retinoyl-Me), 2.53-2.61 (m, 1H, H-2'), 
4.32-4.50 (m, 3H, H-4' and H-5'), 5.29-5.36 (m, 1H, H-3'), 5.76-5.79 (m, 2H, retinoyl), 
6.14-6.24 (m, 9H, H-1 ', retinoyl), 7.02-7.13 (m, 2H, retinoyl), 7.80 (d, JHF= 6.5 Hz. 1H, 
H-6). Referring to the structure on page 33 for numbering. 
4.3 5' -0-Triphenylmethyl-FUdR (Compound 5) 
A mixture of FUdR (123 mg, 0.5 mmol), DMAP (10 mg, 0.08 mmol), TEA (153 
mg, 1.1 mmol), and chlorotriphenylmethane (153 mg, 0.55 mmol) in dry 
dichloromethane (5 mL) was stirred overnight at room temperature. The resultant mixture 
was concentrated and the residue was purified by flash chromatography (continuous 
gradient from dichloromethane to ethyl acetate) to yield 5' -0-triphenylmethyl-FUdR 
(213 mg). The product was then crystallized from dichloromethane-hexane. After 
purification, the chemical yield was found to be 87%. The melting point of the product 
was 116.5-118.5 °C which is comparable with reported melting point of 116 oc (Thomas 
and Montgomery 1962). The Rr value in ethyl acetate was 0.81. 1H NMR (CDCh) data: 
8 2.20-2.24 and 2.41-2.60 (two m, 2H total, H-2'), 3.42-3.47 (m, 2H, H-5'), 4.02-4.07 (m, 
1H, H-4'), 4.45-4.55 (m, 1H, H-3'), 6.22-6.24 (m, 1H, H-1'), 7.20-7.41 (m, 15H, phenyl 
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group), 7.82 (d, JHF = 6.5 Hz, lH, H-6). Referring to the structure on page 33 for 
numbering. 
4.4 3' -0-Retinoyl-5' -0-triphenylmethyl-FUdR (Compound 6) 
To a solution of 5' -0-triphenylmethyl-FUdR (146 mg, 0.30 mmol) and DMAP 
(61 mg, 0.50 mmol) in 8 mL freshly dried benzene, kept at 10 °C, was added retinoyl 
chloride (0.33 mmol) in 5 mL freshly dried benzene gradually. The mixture was stirred 
for one hour at 10 °C, then heated to reflux for 2-3 h. The mixture was cooled to room 
temperature and washed with water (3x15 mL), then dried with Na2S04. Flash 
chromatography (ethyl acetate : chloroform = 1:9) of the residue resulted in 3'-0-
retinoyl-5' -0-triphenylmethyl-FUdR (220 mg). After purification, it was found that the 
chemical yield of 3' -0-retinoyl-5' -0-triphenylmethyl-FUdR was 94%. The Rr value in 
ethyl acetate:hexanes 1:1 (v/v) was 0.68. 1H NMR (CDCh) data: S 0.98 (s, 6H, 2 X 
cyclohexene-Me), 1.08-1.34 (m, 4H, cyclohexene), 1.71 (s, 3H, cyclohexene-Me), 2.02-
2.12 (m, 5H, retinoyl-Me and cyclohexene), 2.33-2.60 (m, 5H, retinoyl-Me and H-2'), 
3.38-3.65 (m, 2H, H-5'), 4.23-4.30 (m, 1H, H-4'), 5.49-5.56 (m, 1H, H-3'), 5.79 (s, 1H, 
retinoyl), 6.12-6.39 (m, 5H, H-1' and retinoyl), 7.02-7.10 (m, 1H, retinoyl), 7.23-7.50 (m, 
15H, phenyl group), 7.88 (d, JHF = 6.5 Hz, 1H, H-6), 8.25 (s, 1H, NH). Referring to the 
structure on page 33 for numbering. 
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4.5 3 '-0-Retinoyl-FUdR (Compound 7) 
To a solution of Compound 6 (200 mg) in ethyl acetate (1.5 ml) was added 1.5 ml 
aqueous 88 % formic acid. The reaction mixture was stirred at room temperature for 1 
hour, then diluted with ethyl acetate (25 ml). After organic layer was washed with half-
saturated NaCI (2 x 10 ml), saturated NaHC03 (3 x 8 ml) and water (2 x 10 ml), it was 
then dried with Na2S04 overnight. After removal of the solvent in vacuo, the residue was 
chromatographed on a silica gel column using gradient elution (0-50 % ethyl acetate in 
hexanes) to afford the product 3' -0-retinoyl-5-fluoro-2' -deoxyuridine (7) (120 mg) as a 
yellow solid. The chemical yield was 90%. The melting point was determined to be 80.5-
82.0 °C. The Rt value in ethyl acetate:hexanes 1:1 (v/v) was 0.34. 1H NMR (CDCb) 
data: 8 1.06 (s, 6H, cyclohexene-Me), 1.09-1.54 (m, 4H, cyclohexene), 1.77 (s, 3H, 
cyclohexene-Me), 1.98-2.11 (m, 5H, retinoyl-Me and cyclohexene), 2.30-2.54 (m, 5H, 
retinoyl-Me and H-2'), 3.95-4.04 (m, 2H, H-5'), 4.15-4.20 (m, 1H, H-4'), 5.40-5.45 (m, 
1H, H-3'), 5.80 (m, IH, retinoyl), 6.14-6.40 (m, 5H, retinoyl and H-1'), 7.04-7.09 (m, IH, 
retinoyl), 8.10 (d, JHF = 7.0 Hz, 1H, H-6), 8.64 (brs, 1H, NH). Referring to the structure 
on page 33 for numbering. 
4.6 3' -0-tert-Butyldimethylsilyl-5' -0-triphenylmethyl-FUdR (Compound 8) 
To a solution of Compound 5 (400 mg, 0.819 mrnol) in dry dimethylformamide 
(DMF) (1.5 mL) was added imidazole (134 mg, 1.98 mmol) and tert-butyldirnethylsilyl 
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chloride (147 mg, 0.98 mmol). The reaction mixture was stirred for 5 h at room 
temperature, then diluted with 80 mL dichloromethane. The resultant mixture was 
washed with water (3 x 40 mL), and was then dried with Na2S04. After filtration and 
removal the solvent, flash chromatography (continuous gradient from hexanes to 
hexanes/ethyl acetate, 1:1, v/v) was carried out to obtain 3' -0-tert-butyldimethylsilyl-5'-
0-triphenylmethyl-FUdR (410 mg). It was found that the chemical yield was 83%. The 
melting point was found to be 144.5-146.5 °C and the Rf value of the product was 0.75 in 
ethyl acetate:hexane 1:1 (v/v). 1H NMR (CDCh) data: 8 0.22 (s, 6H, CH3), 0.86 (s, 9H, 
CH3), 2.12-2.20 and 2.36-2.41 (two m, 2H total, H-2'), 3.37-3.42 (m, 2H, H-5'), 3.97-
4.02 (m, 1H, H-4'), 4.44-4.47 (m, 1H, H-3'), 6.22-6.25 (m, 1H, H-1'), 7.22-7.32 (m, 9H, 
phenyl), 7.33-7.38 (m, 6H, phenyl), 7.83 (d, JHF = 6.5 Hz, 1H, H-6), 8.24 (brs, 1H, NH). 
Referring to the structure on page 33 for numbering. 
4.7 3'-0-tert-Butyldimethylsilyl-FUdR (Compound 9) 
To a solution of Compound 8 (400 mg, 0.67 mmol) in ethyl acetate (2 mL) was 
added 88% formic acid (3 mL). The reaction mixture was stirred at room temperature for 
1 h, then diluted with ethyl acetate (40 mL). The mixture was washed with half-saturated 
NaCI solution (2x10 mL), saturated NaHS04 (2x10 mL) and water (2x10 mL). It was 
then dried with Na2S04 and concentrated. The residue was subjected to flash 
chromatography eluted with continuous gradient from hexane to ethyl acetate/hexane 1:1, 
v/v) to obtain 3 '-0-tert-butyldimethylsilyl-FUdR as a white solid (114 mg). The chemical 
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yield of 3' -0-tert-butyldimethylsilyl-FUdR prepared was 48%. The melting point of 3'-
0-tert-butyldimethylsilyi-FUdR was 173.5-175.0 °C and the Rr value in ethyl 
acetate:hexane 1:1 (v/v) was 0.44. 1H NMR (CDC13) data: 8 0.21 (s, 6H), 0.87 (s, 9H), 
1.89 (brs, 1H, -OH), 2.18-2.22 and 2.24-2.32 (two m, 2H total, H-2'), 3.79-3.82 (m, 1H, 
H-4'), 3.96-4.00 (m, 2H, H-5'), 4.48-4.52 (m, 1H, H-3'), 6.21-6.25 (m, 1H, H-1 '), 8.95 (d, 
JHF = 6.2 Hz, 1H, H-6), 8.22 (s, 1H, NH). Referring to the structure on page 33 for 
numbering. 
4.8 3' -0-tert-Butyldimethylsilyl-5' -0-retinoyl-FUdR (Compound 10) 
To a stirred solution of Compound 9 (100 mg, 0.28 mmol), DMAP (61 mg, 0.5 
mmol) in dry benzene (7 mL), kept at 10 °C, was added retinoyl chloride (0.30 mmol) in 
5 mL benzene dropwise. Mter the reaction mixture was stirred at 10 oc for 1 h, it was 
heated to reflux for 2 h. After cooling down to room temperature, 20 mL ethyl acetate 
was added. The mixture was washed with water (2 x 20 mL), then dried with NazS04. 
Flash chromatography eluted with continuous gradient from hexanes to ethyl 
acetate/hexanes (1:1, v/v) of the residue resulted in 3'-0-tert-butyldimethylsilyl-5'-0-
retinoyl-FUdR (110 mg), which appeared as a yellow solid. The chemical yield was 60%. 
The Rrvalue of the product in ethyl acetate:hexanes 1:1 (v/v) was 0.80. 1HNMR (CDCh) 
data: 8 0.25 (s, 6H), 0.94 (s, 9H), 1.04 (s, 6H, 2 x cyclohexene-Me), 1.44-1.68 (m, 4H, 
cyclohexene), 1.72 (s, 3H, cyclohexene-Me), 1.94-2.08 (m, 5H, retinoyl-Me and 
cyclohexene), 2.35-2.47 (m, 5H, H-2' and retinoyl-Me), 4.06-4.24 (m, 2H, H-5'), 4.28-
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4.48 (m, 2H, H-4', H-3 '), 5.82-5.84 (m, lH, retinoyl), 6.15-6.40 (m, 5H, H- r and 
retinoyl), 7.03-7.08 (m, lH, retinoyl), 7.89 (d, JHF = 6.1 Hz, lH, H-6), 8.12 (s, brs, 1H, 
NH). Referring to the structure on page 33 for numbering. 
4.9 5' -0-retinoyl-FUdR (Compound 11) 
Compound 10 (58 mg, 0.088 mmol) in dry tetrahydrofuran (2.2 ml) was treated 
with anhydrous tetrabutylammonium fluoride (76 mg, 0.29 mmol) and acetic acid (9.37 
~1, 0.164 mmol) for 3.5 h at room temperature. The solution was then concentrated to 
dryness in vacuo. Flash chromatography (gradient, 0-3% v/v methanol in chloroform) of 
the residue yielded a yellow solid compound 9 (41 mg). The chemical yield obtained was 
88%. The Rf value in ethyl acetate:hexanes, 1:1 (v/v) was 0.89. 1H NMR (CDCh) data: 8 
81.03 (s, 6H, cyclohexene-Me), 1.04-1.43 (m, 4H, cyclohexene), 1.72 (s, 3H, 
cyclohexene-Me), 1.80-2.21 (m, 5H, retinoyl-Me and cyclohexene), 2.22-2.45 (m, 5H, 
retinoyl-Me and H-2'), 3.27 (s, IH, -OH), 4.03-4.15 (m, 2H, H-5'), 4.25-4.32 (m, IH, H-
4'), 4.45-4.54 (m, lH, H-3'), 5.56-5.62 (m, 1H, retinoyl), 6.20-6.40 (m, 5H, retinoyl and 
H-1'), 7.20-7.28 (m, 1H, retinoyl), 7.94 (d, JHF = 5.6 Hz, 1H, H-6), 8.46 (brs, 1H, NH). 
Referring to the structure on page 33 for numbering. 
4.10 3' -0-DHA-5' -0-triphenylmethyl-FUdR (Compound 12) 
To a stirred solution of 5' -0-triphenylmethyl-FUdR (79 mg, 0.16 mmol) was 
added dicyclohexylcarbodiimide (DCC) (45.5 mg, 0.22 mmol), DMAP (1-1.5 mg) in 0.5 
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mL dichloromethane, and DHA (56 mg, 0.165 mmol) in 1.0 mL dichloromethane. The 
mixture was stirred for 1.5 h at room temperature, then diluted with dichloromethane, 
washed with water (2x10 mL) and dried with Na2S04. Flash chromatography (gradient 
from hexane to ethyl acetate/hexane 1/1) of the residue yielded an amorphous product of 
3' -0-DHA-5' -0-triphenylmethyl-FUdR (100 mg). The chemical yield was found to be 
79%. The R1in ethyl acetate:hexane 1:1 (v/v) was 0.80. 
4.11 3' -0-DHA-FUdR (Compound 13) 
To a solution of Compound 12 (100 mg, 0.13 mmol) in ethyl acetate (1.5 mL) was 
added 88% formic acid ( 1.5 mL). The reaction mixture was stirred at room temperature 
for 1 h, then diluted with ethyl acetate (25 mL). After organic layer was washed with 
half-saturated NaCl (2x10 mL), saturated NaHC03 (3x8 mL) and water (2x10 mL), it 
was then dried with Na2S04• After removal of the solvent in vacuo, the residue was 
subjected to silica gel column chromatography with a gradient elution system (from 
hexane to hexane/ethyl acetate 1:1, v/v) to afford 3'-0-DHA-FUdR (44 mg) as a waxy 
product. The chemical yield was found to be 65%. The Rf value in ethyl acetate:hexane 
1:1 (v/v) was 0.40. 1H NMR (CDCh) data: 8 0.95-1.05 (t, J = 7.0 Hz, 3H, -CH3), 2.01-
2.07 (q, J = 7.0 Hz, 2H, -CH2-), 2.20-2.30 (m, 2H, H-2') 2.38-2.49 (m, 5H, 5' -OH and-
CH2-CH2-), 2.80-2.94 (m, IOH, (CH2)5), 3.95-4.00 (m, 2H, H-5'), 4.05-4.10 (m, 1H, H-
4'), 5.40-5.53 (m, 13H, (CH=CH)6 and H-3'), 6.32-6.40 (m, 1H, H-1 '), 8.05 (d, JHF = 6.3 
Hz, 1H, H-6), 8.67 (brs, 1H, NH). Referring to the structure on page 33 for numbering. 
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DCC is known as a carboxyl-group activating reagent for the synthesis of peptides 
(Jones 1994). However, in an attempt to synthesize retinoyl derivatives of FUdR using 
DCC as a coupling agent with FUdR and retinoic acid as starting materials, no retinoyl 
derivatives of FUdR were found. Instead, the major product isolated was found to be the 
corresponding N-retinoylurea as a yellow solid (Scheme 4.1 ). The product was purified 
by flash chromatography and the chemical yield was found to be 90%. The structure of 
the product was confirmed by NMR and FAB MS. As shown in Scheme 4.1, DCC 
hydrolyzed partially to 1,3-dicyclohexylurea, which was coupled with the retinoic acid to 
form the observed product N-retinoylurea. 
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o-N=-=N-o + 
DCC 1,3-dicyclohexylurea 
~~~COOH 
1 
N-retinoylurea yield= 90% 
Scheme 4.1. Formation of N-retinoylurea 
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4.12 Isolation of LDL from human plasma 
According to the method described by Schumaker et al. in 1986, human plasma 
was first mixed with PMSF (up to 0.015%) which was used as a protease inhibitor. LDL 
was then obtained based the density gradient which was achieved using K.Br. The density 
of plasma was first adjusted to 1.020 glmL to remove VLDL and then adjusted to 1.063 
glmL to obtain LDL that had a light yellow color. 
4.13 Determination of the protein concentration in LDL preparations 
The protein concentration of the LDL preparations was determined using the 
method of Bradford (Bradford 1976) with BSA as standard. The standard curve was 
prepared using BSA in saline (0.05 mglmL, 0.1 mglmL, 0.2 mglmL, and 0.4 mglmL) 
solutions and is as shown in Figure 4.2. The LDL isolated above was then analyzed and 
the protein concentration was determined using the standard curve. The protein 
concentration in the LDL preparations was found to be 1.2-2.0 mglmL. 
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Figure 4.1. The standard curve prepared using BSA. Each data point represents the 
average of 4-5 measurements. 
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4.14 Incorporation of prodrugs into LDL 
4.14.1 Preparation of 3'-0-retinoyl-FUdR, 5'-0-retinoyl-FUdR, 3'-0-DHA-FUdR and 
3', 5' -di-0-retinoyl-FUdR microemulsions 
The rnicroemulsion of the respective compounds was prepared using the method 
described in Section 3.5.1. They were used for subsequent incorporation of the prodrugs 
into LDL or preparation of complexes of LDL with the respective prodrugs. 
4.14.2 Incorporation of 3' -0-retinoyl-FUdR, 5' -0-retinoyl-FUdR, 3' -0-DHA-FUdR and 
3', 5' -di-0-retinoyl-FUdR into LDL 
It is known that the lipophilicity of the compound to be incorporated affects the 
incorporation efficiency. The retinoic acid and DHA derivatives of FUdR possess 
increased lipophilicity in comparison to FUdR. Therefore, 3', 5' -di-0-retinoyl-FUdR, 3'-
0-retinoyl-FUdR, 5'-0-retinoyl-FUdR and 3'-0-DHA-FUdR were expected to be more 
easily incorporated into LDL than FUdR. The incorporation efficiency expressed as the 
number of molecules incorporated per LDL particle for 3', 5' -di-0-retinoyl-FUdR, 3' -0-
retinoyl-FUdR, 5' -0-retinoyl and 3 '-0-DHA-FUdR was found to be 120, 1000, 870 and 
900, respectively. The lower incorporation efficiency for 3', 5'-di-0-retinoyl-FUdR is 
likely due to the larger molecular size of 3', 5' -di-0-retinoyl-FUdR. 
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4.15 Determination of the prodrug concentration in the prodrug/LDL complex 
The concentration of 3', 5' -di-0-retinoyl-FUdR, 3' -0-retinoyl-FUdR, 5' -0-
retinoyl-FUdR and 3 '-0-DHA-FUdR contained in the prodrug!LDL complex was 
determined using an HP® 1100 HPLC with a Phenomenex® C18 reverse phase column 
(15 em x 3.9 mm, particle size 5 J.lm). The respective prodrugs in the prodrug/LDL 
complexes were first extracted with chloroform as described in Section 3.6. 
The standard prodrug solutions (0.2 mg/mL, 0.4 mg/mL, 0.8 mg/mL, and 1.6 
mg/mL) were prepared in chloroform. HPLC analysis was performed by injecting 10 J.I.L 
of each sample with methanol/HzO (9/1, v/v) at 1.0 rnL!min as the mobile phase and UV 
detection at 267 nm. Under these conditions, the retention times for 3 '-0-retinoyl-FUdR, 
5' -0-retinoyl-FUdR, 3' -0-DHA-FUdR and 3', 5' -di-0-retinoyl-FUdR were 9, 6, 7 and 5 
min, respectively. The area under the curve of the respective peak was calculated. The 
analysis for each sample was repeated three times. A standard curve was obtained by 
plotting the concentrations of the standard samples versus the corresponding peak area. 
The analysis was repeated three times for each sample and the results were expressed as 
the average of three analysis. The standard curve was used to determine the concentration 
of prodrug in the prodrug!LDL complexes. 
4.16 Cytotoxicity of 3' -0-retinoyl-FUdR, 5' -0-retinoyl-FUdR, 3' ,5' -di-0-retinoyl-
FUdR, 3' -0-DHA-FUdR and their LDL complexes determined in Hela cells 
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The cytotoxicity of 3 ', 5' -di-0-retinoyi-FUdR/LDL, 3 '-0-retinoyi-FUdRILDL, 
5' -0-retinoyl-FUdR/LDL, 3 ', 5' -di-0-retinoyl-FUdR in ethanol, 3 '-0-retinoyi-FUdR in 
ethanol, 5' -0-retinoyl-FUdR in ethanol, 3' -0-DHA-FUdR in ethanol and FUdRIPBS 
were determined using the MTT assay in Hela cells (cervical cancer). Tests were repeated 
at least twice at different times for each compound. 
Since the prodrugs were incorporated into LDL, it was essential to ensure that the 
amount of LDL used in this study was not toxic and did not have any effect on the cells. 
The cytotoxicity of LDL (0.125 mg/mL, 0.25 mg/mL and 0.50 mg/mL, protein 
concentration) in Hela cell line was determined using MTT assay. Our results showed 
that LDL (0.125 mg/mL, 0.25 mg/mL and 0.50 mg/mL) did not cause any cell death. 
Since the concentration of LDL in each of the prodrug!LDL complex was less than 0.35 
mg/mL, the cytotoxicity of prodrug!LDL was attributed to the prodrug alone. 
Since ethanol was used to dissolve the prodrugs, 3' -0-retinoyl-FUdR, 5' -0-
retinoy-FUdR 3'-0-DHA-FUdR and 3', 5'-di-0-retinoyl-FUdR, the cytotoxicity of 
ethanol was determined using the MTT assay. It was found that ethanol at the 
concentrations tested (1.5%, 3% and 6%) was not toxic to Hela cells. The concentration 
of ethanol used in preparation of prodrugs was thus kept to be 3% or lower. 
The results of cytotoxicity determined in Hela cells are shown in Figures 4.2 and 
4.3, and Table 4.1. As shown in Figure 4.2, the results demonstrated that all prodrugs, 
3' -0-DHA-FUdR, 3' -0-retinoyl-FUdR, 5' -0-retinoyl-FUdR and 3', 5' -di-0-retinoyi-
FUdR, were more cytotoxic than FUdR while 3'-0-DHA-FUdR and 3'-0-retinoyl-FUdR 
were more potent than 5' -0-retinoyl-FUdR and 3', 5'.-di-0-retinoyl-FUdR, especially 
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upon incubation of 48 h. We believe that this is because 3'-esters are more easily 
hydrolyzed resulting in two active drugs released with different anticancer mechanisms. 
The hydrolysis process for the 5'- and 3', 5'- derivatives is relatively slow. Our data also 
showed that 3' -0-DHA-FUdR was superior to 3' -0-retinoyl-FUdR and the IC50 values 
upon incubation of 24 h are 48 J..l.M and 92 J..l.M, respectively. One explanation could be 
that the hydrolysis of the DHA derivative may be faster than the retinoyl derivative, or 
DHA may alter the pharmacokinetics of DHA conjugated FUdR. It has been reported that 
the DHA-paclitaxel conjugation showed increased cytotoxicity in certain tumors such as 
CD2F1 tumor compared with paclitaxel due to the alteration of pharmacokinetics of 
DHA-paclitaxel by DHA (Bradley et al. 2001). The other explanation could be that the 
Hela cells are more sensitive to DHA than retinoic acid. DHA has shown to enhance 
anticancer drugs' cytotoxicity, such as paclitaxel and doxorubicin, in many human breast 
cancer cell lines and other cancer cell lines (Menendez et al. 2001, Liu and Tan 2000). 
Although FUdR did not show any cytotoxicity upon incubation with Hela cells for 24 h, 
it was quite effective after 72 h with an IC50 of 10 J..l.M. As shown in Figure 4.3, all the 
prodrug!LDL were more effective than FUdR upon incubation of 24 and 48 h. However, 
the cytotoxicity demonstrated by the prodrug!LDL was found to be similar to that of 
FUdR upon incubation of 72 h. The IC50 values are summarized in Table 4.1. It has been 
reported that Hela cells internalize LDL by a receptor-mediated process (Johnson et al. 
1983, Lestavel-Delattra et al. 1992). Previously, it has been demonstrated that the loading 
procedure we used did not alter the recognition of LDL by the LDL receptors on the Hela 
cell surface (Kader 1998). Our results suggested that the respective prodrug!LDL 
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complex is recognized by the LDL receptors. Upon internalization, hydrolysis of the 
prodrug would result in two active anticancer compounds, FUdR and DHA or FUdR and 
retinoic acid. 
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Figure 4.2. Cytotoxicity of 3' -0-DHA-FUdR, 3' -0-retinoyl-FUdR, 5' -0-retinoyl-FUdR, 
and 3', 5' -di-0-retinoyl-FUdR dissolved in ethanol, and FUdR dissolved in PBS in Hela 
cells upon incubation of 24 h, 48 hand 72 h, respectively. Student T-test was carried out 
for the statistical analysis. 
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Figure 4.3. Cytotoxicity of 3' -0-retinoyl-FUd.R/LDL, 5' -0-retinoyl-FUdR/LDL, 3', 5'-
di-0-retinoyl-FUdR/LDL, and FUdR dissolved in PBS in Hela cells upon incubation of 
24 h, 48 h and 72 h, respectively. Student T-test was carried out for the statistical 
analysis. 
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Table 4.1 Summary of IC50 (!lM) values determined m Hela cells under different 
conditions 
Compounds tested ICso values (!lM) 
24h 48h 72h 
3 '-0-retinoyl-FUdRJLDL 10 7.9 6.5 
5' -0-retinoyl-FUdRJLDL 11 8.4 6.5 
3', 5' -0-diretinoyl-FUdRILDL 12 8.8 6.8 
3' -0-retinoyl-FUd.Ra 92 13 7.3 
5' -0-retinoyl-FUdRa 100 39 11 
3' -0-DHA-FUd.Ra 48 4.4 1.6 
3', 5' -di-0-retinoyl-FUdRa 102 43 20 
FUdRb 765 52 10 
Notes: 
a. The compounds were dissolved in ethanol and m no case did the final 
concentration of ethanol exceed 3 %. 
b. FUdR was dissolved in PBS (pH 7.4) and in no case did the final concentration of 
PBS exceed 2 %. 
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4.17 Cytotoxicity of 3' -0-retinoyl-FUdR, 5' -0-retinoyl-FUdR, 3' ,5' -di-0-retinoyl-
FUdR, 3' -0-DHA-FUdR and their LDL complexs determined in MB231 and MCF7 cells 
The cytotoxicity of 3'-0-retinoyl-FUdR/LDL, and 3'-0-DHA-FUdR/LDL 
together with 3', 5' -di-0-retinoyl-FUdR, 3' -0-retinoyl-FUdR, 5' -0-retinoyl-FUdR, 3 '-
0-DHA-FUdR in ethanol and FUdR in PBS were determined using the MTT assay in 
MB231 and MCF7 (breast cancer). Tests were repeated at least twice at different times 
for each cell line and each compound. 
Since ethanol was used to dissolve the prodrugs, the cytotoxicity of ethanol (1.5%, 
3% and 6%) was determined in MB231 and MCF7. The cytotoxicity of LDL (0.125 
mg/mL, 0.25 mg/mL and 0.50 mg/mL) in MB231 and MCF7 cells was also evaluated. 
Our results showed that both ethanol and LDL at the concentrations tested were not toxic 
to either MB231 or MCF7 cells. The concentration of ethanol used in preparation of 
prodrugs was kept to be 3% or lower and the concentration of LDL in each prodrug/LDL 
complex was less than 0.35 mg/mL. 
The results of cytotoxicity of the four respective prodrugs (3' -0-retinoyl-FUdR, 
5' -0-retinoyl-FUdR, 3', 5' -di-0-retinoyl-FUdR, 3' -0-DHA-FUdR) dissolved in ethanol 
in MB231 upon incubation of 24 and 72 h are shown in Figure 4.4. The results in MCF7 
upon incubation of 24 and 48 h are shown in Figure 4.5. It is demonstrated that the 
prodrugs were more potent than their parent drug, FUdR, upon incubation of 24 h. 
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However, upon incubation of 72 h with MB231 cells, the difference of ICso vall;Jes 
between the respective prodrugs and FUdR was not significant. FUdR did not exert 
cytotoxicity in MCF7 upon incubation of 24 or 48 h. In addition, 3 '-0-DHA-FUdR was 
superior to the retinoyl esters of FUdR, suggesting that the hydrolysis of the DHA 
derivative may be faster than the retinoyl derivatives or the cells may be more sensitive to 
DHA than to retinoic acid. 
The cytotoxicity of 3' -0-DHA-FUd.R/LDL and 3' -0-retinoyl-FUd.R/LDL was 
evaluated in MB231 and MCF7 together with FUdR in PBS. The results are shown in 
Figures 4.6 and 4.7, and Table 4.2. It is interesting to note that the respective 
prodrug/LDL complexes did not demonstrate improved cytotoxicity. 
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Figure 4.4. Cytotoxicity of 3' -0-DHA-FUdR, 3' -0-retinoyl-FUdR, 5' -0-retinoyl-FUdR 
and 3', 5' -di-0-retinoyl-FUdR dissolved in ethanol and FUdR dissolved in PBS in 
MB231 cells upon incubation of 24 hand 72 h, respectively. Student T-test was carried 
out for the statistical analysis. 
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Figure 4.5. Cytotoxicity of 3'-0-DHA-FUdR, 3'-0-retinoyl-FUdR, 5'-0-retinoyl-FUdR, 
3', 5' -di-0-retinoyl-FUdR dissolved in ethanol and FUdR dissolved in PBS in MCF7 
cells upon incubation of 24 hand 48 h, respectively. Student T-test was carried out for 
the statistical analysis. 
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Figure 4.6. Cytotoxicity of 3 '-0-DHA-FUdRILDL, 3 '-0-retinoyl-FUdRILDL and FUdR 
dissolved in PBS in MB231 cells upon incubation of 24 hand 72 h, respectively. Student 
T -test was carried out for the statistical analysis. 
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Figure 4.7. Cytotoxicity of 3'-0-DHA-FUd.R/LDL, 3'-0-retinoyl-FUdR/LDL, and FUd.R 
dissolved in PBS in MCF7 cells upon incubation of 24 hand 48 h, respectively. Student 
T -test was carried out for the statistical analysis. 
84 
Table 4.2 Summary of IC5o (~M) values determined in MB231 and MCF7 cells under 
different conditions 
Cell Compounds tested IC so values (J.LM) 
line 24h 48h 72h 
3' -0-retinoyl-FUdR/LDL 98 f 40 
3' -0-DHA-FudR/LDL 22 I 5.6 
3' -0-retinoyl-FUdRa 87 I 34 
MB231 5' -0-retinoyl-FUdRa 79 I 44 
3' -0-DHA-FudRa 45 I 4.9 
3', 5' -di-0-retinoyl-FUdRa 126 I 32 
FUdRb 195 I 5.8 
3' -0-retinoyl-FUdR/LDL 231 88 I 
3' -0-DHA-FUdR/LDL 54 34 I 
3' -0-retinoyl-FUdRa 243 102 I 
MCF7 5' -0-retinoyl-FUdRa 357 223 I 
3' -0-DHA-FUdRa 92 41 I 
3', 5' -di-0-retinoyl-FUdRa 387 274 I 
FUdRb d I 00 00 
Notes: 
a. Prodrugs were dissolved in ethanol, and in no case did the final concentration of 
ethanol in the medium exceed 3%. 
b. FUdR was dissolved in PBS (pH 7.4), and in no case did the final concentration 
of PBS in the medium exceed 2%. 
c. Not determined. 
d. IC5o value was greater than 5,000 (~M). 
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4.18 Cytotoxicity of 3' -0-retinoyl-FUdR, 5' -0-retinoyl-FUdR, 3' ,5' -di-0-retinoyl-
FUdR, and 3' -0-DHA-FUdR in ethanol determined in HepG2 cells 
The cytotoxicity of 3', 5' -di-0-retinoyl-FUdR in ethanol, 3' -0-retinoyl-FUdR in 
ethanol, 5' -0-retinoyl-FUdR in ethanol, 3' -0-DHA-FUdR in ethanol and FUdR 
dissolved in PBS were determined using the MTT assay in HepG2 (hepatic) cells. Tests 
were repeated at least twice at different times for each cell line and each compound. 
Again the cytotoxicity of ethanol was determined using the MTT assay. Ethanol 
at the concentrations tested (1.5%, 3% and 6%) was not found to be toxic to HepG2 cells. 
The concentration of ethanol used in the preparation of prodrug solutions was kept to be 
3% or lower. 
The results of c)'Wtoxicity of the respective prodrugs are illustrated in Figure 4.8 
and Table 4.3. It was found that the four prodrugs were more potent than their parent 
drug, FUdR, while 3' -0-retinoyl-FUdR and 3' -0-DHA-FUdR were superior to 5' -0-
retinoyl-FUdR and 3 ', 5' -di-0-retinoyl-FUdR. 
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Figure 4.8. Cytotoxicity of 3' -0-DHA-FUdR, 3 '-0-retinoyl-FUdR, 5' -0-retinoyl-FUd.R, 
and 3', 5' -di-0-retinoyl-FUd.R dissolved in ethanol, and FUdR dissolved in PBS in 
HepG2 cells upon incubation of 24 h and 48 h, respectively. Student T-test was carried 
out for the statistical analysis. 
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Table 4.3 Summary of IC50 (J..I.M) values determined in HepG2 cells under different 
conditions 
Compounds tested IC so values (J.!M) 
24h 48h 
3 '-0-retinoyl-FUdRa 33 7.8 
5' -0-retinoyl-FUdRa 85 5.2 
3' -0-DHA-FUdRa 35 14 
3', 5' -di-0-retinoyl-FUdRa 321 19 
FUdRb ooc 214 
Notes: 
a. Prodrugs were dissolved in ethanol, and in no case did the final concentration of 
ethanol in the medium exceed 3%. 
b. FUdR was dissolved in PBS (pH 7.4), and in no case did the final concentration 
of PBS in the medium exceed 2%. 
c. ICso value was greater than 5,000 (J..I.M). 
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4.19 In vitro differentiation test in CEM!f4 cells 
Retinoic acid and DHA released from the prodrugs were expected to be able to 
induce malignant cell differentiation and then to lead to cell apoptosis. Therefore, 
differentiation effect of prodrugs in ethanol was examined in leukemia cell line, CE:tvlff4 
cells. The results are shown in Table 4.4. 3' -0-DHA-FUdR, 3' -0-retinoyl-FUdR and 5'-
0-retinoyl-FUdR were shown to be slightly superior to FUdR. 
Table 4.4 Differentiation activity of retinoic acid, FUdR, 3'-0-DHA-FUdR, 3'-0-
retinoyl-FUdR and 5' -0-retinoyl-FUdR determined in CEM!f4 cells 
Concentration (J..LM) I Differentiation(% NBT -positive cells) 
Compounds tested lJ..LM 0.1J.1.M 0.01 J..LM 
Retinoic acid 43% 40% 32% 
FUdR 18% 14% 14% 
3' -0-retinoyl-FUdR 29% 25% 18% 
3 '-0-DHA-FUdR 20% 20% 14% 
5' -0-retinoyl-FUdR 27% 21% 16% 
Control < 10% 
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Chapter 5 Conclusions 
In this study, four FUdR derivatives (3' -0-retinoyl-FUdR, 5' -0-retinoyl-FUdR, 
3' -0-DHA-FUdR and 3', 5' -di-0-retinoyl-FUdR) were designed and synthesized as 
prodrugs of FUdR. It is believed that the respective prodrugs upon being taken into cells 
would be hydrolyzed to generate two compounds (FUdR and retinoic acid or FUdR and 
DHA) which would act as anticancer drugs via different mechanisms. To facilitate the 
specific uptake of these prodrugs by cancer drugs, LDL was used as a drug carrier. It is 
known that most cancer cells express elevated levels of LDL receptors on their surface 
compared to normal cells. The prodrugs synthesized were thus incorporated into LDL 
resulting in the formation of prodrug/LDL complexes. It was found that the incorporation 
efficiencies of the prodrugs were > 120 molecules per LDL particle. 
The cytotoxicity of 3' -0-retinoyl-FUdRILDL, 5' -0-retinoyl-FUdRILDL, and 3', 
5' -di-0-retinoyl-FUd.R/LDL complexes together with 3' -0-retinoyl-FUdR, 5' -0-
retinoyl-FUdR, 3', 5'-di-0-retinoyl-FUdR, 3'-0-DHA-FUdR, dissolved in ethanol and 
FUdR dissolved in PBS, were tested in cervical cancer cell line, Hela cells. In all cases, 
the prodrugs showed increased cytotoxicity compared with the parent drug, FUdR. Our 
results also showed the cytotoxicity of prodrugs/LDL complexes was increased compared 
with the corresponding prodrug dissolved in ethanol in Hela cells, especially upon 
incubation of 24 h (Table 4.1). It has been reported that LDL receptors are expressed on 
the surface of the Hela cells which internalize LDL particles via a receptor-mediated 
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process (Johnson et al. 1983; Lestavel-Delattra et al. 1992). The increased cytotoxicity 
demonstrated by the prodrug!LDL complexes is consistent with the increased cell surface 
LDL receptor levels on Hela cells which resulted in the enhanced cellular uptake of 3' ,5'-
di-0-retinoyl-FUdRILDL, 3' -0-retinoyl-FUdR and 5' -0-retinoyl-FUdR. The results 
showed that LDL could be a useful drug carrier for targeting anticancer drugs to Hela 
cells. 
The cytotoxicity of 3' -0-retinoyl-FUdR/LDL, 5' -0-DHA-FUdRILDL complex 
together with 3' -0-retinoyl-FUdR, 5' -0-retinoyl-FUdR, 3', 5' -di-0-retinoyl-FUdR, 3'-
0-DHA-FUdR, dissolved in ethanol and FUdR dissolved in PBS, were also tested in 
breast cancer cell lines, MB231 and MCF7 cells. Our results indicated that all prodrugs 
were more potent than the parent drug, FUdR. However, the prodrug!LDL complexes 
(3'-0-retinoyl-FUdRILDL and 3'-0-DHA-FUdRILDL) did not demonstrate much 
improved cytotoxicity in MCF7 and MB231 over the corresponding prodrugs dissolved 
in ethanol (Table 4.2). 
In addition, the cytotoxicity of 3' -0-retinoyl-FUdR, 5' -0-retinoyl-FUdR, 3', 5'-
di-0-retinoyl-FUdR, 3' -0-DHA-FUdR dissolved in ethanol, and FUdR dissolved in PBS, 
were tested in hepatic cancer cellline-HepG2 cells. Our results showed that all prodrugs 
showed the increased cytotoxicity compared with the parent drug, FUdR. 
Among the four prodrugs (3' -0-retinoyl-FUdR, 5' -0-retinoyl-FUdR, 3' -0-DHA-
FUdR and 3',5'-di-0-retinoyl-FUdR), 3'-0-DHA-FUdR and 3'-0-retinoyl-FUdR were 
found to be more potent than the other two prodrugs. This may indicate that the different 
derivatives have different hydrolysis rates and the 3' -esters are more susceptible to 
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hydrolysis than the 5'- or 3' ,5' -esters. More studies are needed in this regard. A 
comparison of 3'-0-DHA-FUdR and 3'-0-retinoyl-FUdR showed that 3'-0-DHA-FUdR 
was superior to 3' -0-retinoyl-FUdR when incubated with Hela and MCF7 cells, which 
may suggest that the cells tested are more sensitive to DHA than retinoic acid or the 3'-
0-DHA derivative undergoes a faster hydrolysis. However, more studies are needed. 
Differentiation effect of the prodrugs dissolved in ethanol (3' -0-DHA-FUdR, 3'-
0-retinoyl-FUdR and 5' -0-retinoyi-FUdR) was examined in leukemia cell line, CEM!f4 
cells. The results showed that 3'-0-DHA-FUdR, 3'-0-retinoyl-FUdR and 5'-0-retinoyl-
FUdR were slightly superior to FUdR. 
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